C:\Program Files\Stnexp\Queries\10069314.str





ring nodes :
1 2 3 4 5 6 7 8 9 10
ring bonds :
1-2 1-6 2-3 2-10 3-4 4-5 4-7 5-6 5-9 7-8 8-9
exact/norm bonds :
2-10 4-7 5-9 7-8 8-9
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom

10/069,314

```
=> d his

     (FILE 'HOME' ENTERED AT 15:23:45 ON 02 JUN 2004)

     FILE 'REGISTRY' ENTERED AT 15:23:56 ON 02 JUN 2004
L1              STRUCTURE UPLOADED
L2              QUE L1
L3            3 S L2
L4          712 S L2 SSS FUL

     FILE 'CAPLUS' ENTERED AT 15:24:42 ON 02 JUN 2004

     FILE 'REGISTRY' ENTERED AT 15:24:54 ON 02 JUN 2004
L5       181095 S 5-5-6/SZ
L6          171 S L4 AND L5
L7          541 S L4 NOT L6
L8       583392 S 5-6-6/SZ
L9           98 S L7 AND L8
L10         443 S L7 NOT L9
L11         222 S L10 AND SPIRO

     FILE 'CAPLUS' ENTERED AT 15:33:47 ON 02 JUN 2004
L12         216 S L4
L13         ANALYZE L12 1- RN HIT :     638 TERMS

     FILE 'REGISTRY' ENTERED AT 15:34:30 ON 02 JUN 2004
L14        1074 S 18008?/RN
L15           5 S 18556-07-5/RN OR 51773-01-4/RN OR 204-43-3/RN OR 318-59-2/RN

     FILE 'CAPLUS' ENTERED AT 15:43:18 ON 02 JUN 2004
L16          35 S L6
L17          35 S L12 AND L16

=> d ibib abs hitstr 1-35
```

L17 ANSWER 1 OF 35 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:725606 CAPLUS
DOCUMENT NUMBER: 140:228423
TITLE: Quantitative structure-activity relationships (QSAR): studies of inhibitors of tyrosine kinase
AUTHOR(S): Shen, Qi; Lu, Qing-Zhang; Jiang, Jian-Hui; Shen, Guo-Li; Yu, Ru-Qin
CORPORATE SOURCE: College of Chemistry and Chemical Engineering, State Key Laboratory of Chemo/Biosensing and Chemometrics, Hunan University, Changsha, 410082, Peop. Rep. China
SOURCE: European Journal of Pharmaceutical Sciences (2003), 20(1), 63-71
CODEN: EPSCED; ISSN: 0928-0987
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB A quant. structure-activity relationship (QSAR) study of the 1-phenylbenzimidazoles as inhibitors of the platelet-derived growth factor receptor (PDGFR) was performed. Some new electronic parameters Qo, Qm and Qp are suggested for characterizing the effect of substituents. Many other descriptors are also used which are selected by evolution algorithm (EA) using modified Cp as objective function proposed by the present authors. The descriptor Qm is shown to be an important variable to express effect of substituents. The variable selection shows that spatial descriptors are most important variables revealing important properties of the inhibitors. Electron-releasing substitutes at 5-position and the absence of bulky groups at 4,7-positions of the parent structure can enhance inhibitor activity. Principal component anal. is performed to classify this series of compds.

IT **667919-07-5**
RL: PAC (Pharmacological activity); PRP (Properties); BIOL (Biological study)
(quant. structure-activity relationships (QSAR) of 1-phenylbenzimidazoles as inhibitors of PDGF receptor tyrosine kinase)
RN 667919-07-5 CAPLUS
CN 3H-Furo[3,2-e]benzimidazole, 7,8-dihydro-7-methyl-3-phenyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 2 OF 35 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:717764 CAPLUS
DOCUMENT NUMBER: 139:230775
TITLE: Preparation of pyranoindazoles and their use for the treatment of glaucoma
INVENTOR(S): Chen, Hwang-hsing; May, Jesse A.; Severns, Bryon S.
PATENT ASSIGNEE(S): Alcon, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 33 pp., Cont.-in-part of Appl. PCT/US02/16861.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003171418	A1	20030911	US 2002-316600	20021211
US 6696476	B2	20040224		
WO 2002098350	A2	20021212	WO 2002-US16861	20020530
WO 2002098350	A3	20030227		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-295429P P 20010601
WO 2002-US16861 A2 20020530
OTHER SOURCE(S): MARPAT 139:230775
GI



I



II

AB Pyranoindazoles of formula I [R1, R2 = H, alkyl; R3, R4 = H, alkyl; R3R4 = heterocycle; R5 = H, halo, alkyl; R6, R7 = H, halo, CN, alkylthio, alkyl; R8, R9 = H, OH, alkyl, alkoxy, oxo, etc.; A = (CH2)n, CO, CH-alkyl; n = 0-2; X, Y = N, C] are disclosed. Also disclosed are methods for the lowering and controlling of normal or elevated intraocular pressure as

L17 ANSWER 2 OF 35 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
well as a method for the treatment of glaucoma using compns. contg. one or more of the compds. of the present invention. Thus, II was prepd. and had IC50 of 2.25 nM and EC50 of 65.3 nM in 5-HT2A receptor binding assay.

IT **594872-09-0P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyranoindazoles for the treatment of glaucoma)
RN 594872-09-0 CAPLUS
CN 3H-Furo[3,2-e]indazole-7-acetamide, 1-[(2S)-2-aminopropyl]-7,8-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L17 ANSWER 3 OF 35 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:595181 CAPLUS
DOCUMENT NUMBER: 140:104436
TITLE: Establishment of substituent effects in the DNA binding subunit of CBI analogues of the duocarmycins and CC-1065
AUTHOR(S): Parrish, Jay P.; Kastrinsky, David B.; Stauffer, Frederic; Hedrick, Michael P.; Hwang, Inkyu; Boger, Dale L.
CORPORATE SOURCE: Department of Chemistry and The Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, CA, 92037, USA
SOURCE: Bioorganic & Medicinal Chemistry (2003), 11(17), 3815-3838
CODEN: BMECEP; ISSN: 0968-0896
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB An extensive series of CBI analogs of the duocarmycins and CC-1065 exploring substituent effects within the first indole DNA binding subunit is detailed. In general, substitution at the indole C5 position led to cytotoxic potency enhancements that can be ≥1000-fold providing simplified analogs containing a single DNA binding subunit that are more potent (IC50=2-3 pM) than CBI-TMI, duocarmycin SA, or CC-1065.

IT **647022-34-2P**
RL: PAC (Pharmacological activity); PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(substituent effects in the DNA binding subunit of CBI analogs of the duocarmycins and CC-1065)
RN 647022-34-2 CAPLUS
CN 1H-Benz[e]indol-5-ol, 1-(chloromethyl)-3-[(1,6-dihydro-2H-furo[3,2-e]indol-7-yl)carbonyl]-2,3-dihydro-, (1S) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **647022-64-8P**
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(substituent effects in the DNA binding subunit of CBI analogs of the duocarmycins and CC-1065)
RN 647022-64-8 CAPLUS
CN 4H-Benzo[e]cycloprop[c]indol-4-one, 2-[(2,6-dihydro-1H-furo[3,2-e]indol-7-yl)carbonyl]-1,2,9,9a-tetrahydro-, (8bR,9aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L17 ANSWER 3 OF 35 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



REFERENCE COUNT: 92 THERE ARE 92 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L17 ANSWER 4 OF 35 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:977961 CAPLUS
DOCUMENT NUMBER: 138:49896
TITLE: Human growth hormone antagonists
INVENTOR(S): Cochran, Andrea G.
PATENT ASSIGNEE(S): Genentech, Inc., USA
SOURCE: PCT Int. Appl., 45 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002102978	A2	20021227	WO 2002-US18789	20020614
WO 2002102978	A3	20030410		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003096852	A1	20030522	US 2002-172247	20020614
EP 1401431	A2	20040331	EP 2002-744325	20020614
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

PRIORITY APPLN. INFO.: US 2001-298358P P 20010615
WO 2002-US18789 W 20020614
OTHER SOURCE(S): MARPAT 138:49896
GI



I

AB The invention discloses the use of antagonist I (X = N, CH; R1, R2, R3, R4
= H, halogen, hydroxy, carboxy, nitro, amino etc.; R5 = H, alkyl, alkenyl,
alkynyl etc.] for treating disorders in mammals in which human growth hormone is implicated.

L17 ANSWER 4 OF 35 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
IT **147610-38-6**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(human growth hormone antagonists)
RN 147610-38-6 CAPLUS
CN 1H-Furo[2,3-f]benzimidazole, 6,6,7,7-tetrafluoro-6,7-dihydro-2-(trichloromethyl)- (9CI) (CA INDEX NAME)



L17 ANSWER 5 OF 35 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:152691 CAPLUS
DOCUMENT NUMBER: 134:193418
TITLE: Dihydrobenzofuran derivatives, process for the preparation thereof and agents
INVENTOR(S): Ohkawa, Shigenori; Hashimoto, Tadatoshi; Tsukamoto, Tetsuya
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 113 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001014385	A1	20010301	WO 2000-JP5524	20000818
W: AE, AG, AL, AM, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
JP 2001131180	A2	20010515	JP 2000-254232	20000818
EP 1213290	A1	20020612	EP 2000-953480	20000818
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				

PRIORITY APPLN. INFO.: JP 1999-234719 A 19990820
WO 2000-JP5524 W 20000818
OTHER SOURCE(S): MARPAT 134:193418
GI



I



II

AB Compds. represented by general formula [I; wherein A is a nonarom. five- to seven-membered nitrogenous heterocycle which may be addnl. substituted;

L17 ANSWER 5 OF 35 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

B is a benzene ring which may be addnl. substituted; C is a dihydrofuran ring which may be addnl. substituted; and R is hydrogen or acyl, provided that: (1) when A is a nonarom. five-membered nitrogenous ring substituted with a group represented by the general formula: (CH2)mN(R'')COR' (wherein R' is an optionally substituted hydrocarbon group, optionally substituted amino, or an optionally substituted heterocyclic group; R''is hydrogen or an optionally substituted hydrocarbon group; and m is an integer of 1 to 4), B is an addnl. substituted benzene ring, and (2) when A is a nonarom. six-membered nitrogenous oxo heterocycle, B is a wholly substituted benzene ring] or salts thereof are prepd. These compds. exhibit excellent inhibitory activity against the formation of peroxylipid and are useful as inhibitors against the formation thereof for the prevention of cerebral vascular disorders, head trauma, neurodegenerative diseases, Parkinson's disease, Alzheimer's disease, urination disorders, pollakiuria, or restenosis after percutaneous transluminal coronary angioplasty (PTCA). Thus, 1,6,7,8-tetrahydro-2-(iodomethyl)-2,4,5,7,7-pentamethyl-2H-furo[3,2-e]indole, N-(diphenylmethyl)-4-piperidineamine, K2CO3, and DMF were stirred at 180° for 3 h to give, after the treatment with HCl/MeOH, 87% N-(diphenylmethyl)-1-[(1,6,7,8-tetrahydro-2,4,5,7,7-pentamethyl-2H-furo[3,2-e]indol-2-yl)methyl]-4-piperidineamine (II) dihydrochloride. II.2HCl showed IC50 of 0.057 μM for inhibiting the lipid peroxide formation in rat cerebral homogenate.

IT **327175-34-8P**, 1,6,7,8-Tetrahydro-2,2,4,5-tetramethyl-2H-furo[3,2-e]indole **327175-35-9P**, 1,6,7,8-Tetrahydro-2,2,4,5,7-pentamethyl-2H-furo[3,2-e]indole hydrochloride **327175-36-0P**, 1,6,7,8-Tetrahydro-2,2,4,5,7,7-hexamethyl-2H-furo[3,2-e]indole **327175-37-1P**, 1,6,7,8-Tetrahydro-2,2,4,5,7,7-hexamethyl-2H-furo[3,2-e]indole oxalate **327175-42-8P 327175-43-9P 327175-44-0P 327175-45-1P 327175-48-4P 327175-49-5P 327175-50-8P 327175-51-9P 327175-52-0P 327175-53-1P 327175-55-3P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of hydrobenzofuran derivs. as inhibitors of lipid peroxide formation for preparation of various diseases)

RN 327175-34-8 CAPLUS
CN 2H-Furo[3,2-e]indole, 1,6,7,8-tetrahydro-2,2,4,5-tetramethyl- (9CI) (CA INDEX NAME)



L17 ANSWER 5 OF 35 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 327175-35-9 CAPLUS
CN 2H-Furo[3,2-e]indole, 1,6,7,8-tetrahydro-2,2,4,5,7-pentamethyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 327175-36-0 CAPLUS
CN 2H-Furo[3,2-e]indole, 1,6,7,8-tetrahydro-2,2,4,5,7,7-hexamethyl- (9CI) (CA INDEX NAME)



RN 327175-37-1 CAPLUS
CN 1H-Furo[3,2-e]indole, 2,6,7,8-tetrahydro-2,2,4,5,7,7-hexamethyl-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 327175-36-0
CMF C16 H23 N O

L17 ANSWER 5 OF 35 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



CM 2

CRN 144-62-7
CMF C2 H2 O4

RN 327175-42-8 CAPLUS
CN 2H-Furo[3,2-e]indole, 1,6,7,8-tetrahydro-2,4,5-trimethyl-2-[(4-phenyl-1-piperidinyl)methyl]- (9CI) (CA INDEX NAME)



RN 327175-43-9 CAPLUS
CN 1H-Furo[3,2-e]indole, 2,6,7,8-tetrahydro-2,4,5-trimethyl-2-[(4-phenyl-1-piperidinyl)methyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 327175-42-8
CMF C25 H32 N2 O



CM 2

L17 ANSWER 5 OF 35 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 327175-44-0 CAPLUS
CN 2H-Furo[3,2-e]indole, 1,6,7,8-tetrahydro-2,4,5,7,7-pentamethyl-2-[(4-phenyl-1-piperidinyl)methyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 327175-45-1 CAPLUS
CN 2H-Furo[3,2-e]indole, 1,6,7,8-tetrahydro-2,4,5,7,7-pentamethyl-2-[(4-phenyl-1-piperidinyl)methyl]- (9CI) (CA INDEX NAME)



RN 327175-48-4 CAPLUS
CN 2H-Furo[3,2-e]indole, 1,6,7,8-tetrahydro-2,4,5,7,7-pentamethyl-2-[(1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

L17 ANSWER 5 OF 35 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



● HCl

RN 327175-49-5 CAPLUS
CN 2H-Furo[3,2-e]indole, 1,6,7,8-tetrahydro-2,4,5,7,7-pentamethyl-2-[(1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)methyl]- (9CI) (CA INDEX NAME)



RN 327175-50-8 CAPLUS
CN 4-Piperidinamine, N-(diphenylmethyl)-1-[(1,6,7,8-tetrahydro-2,4,5,7,7-pentamethyl-2H-furo[3,2-e]indol-2-yl)methyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 327175-51-9 CAPLUS

L17 ANSWER 5 OF 35 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
CN 2H-Furo[3,2-e]indole, 2-[[4-[3-(diphenylmethoxy)propyl]-1-piperidinyl]methyl]-1,6,7,8-tetrahydro-2,4,5-trimethyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 327175-52-0 CAPLUS
CN 2-Benzothiazolamine, N-methyl-N-[1-[(1,6,7,8-tetrahydro-2,4,5,7,7-pentamethyl-2H-furo[3,2-e]indol-2-yl)methyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 327175-53-1 CAPLUS
CN 3-Piperidinecarboxylic acid, 4-phenyl-1-[(1,6,7,8-tetrahydro-2,4,5-trimethyl-2H-furo[3,2-e]indol-2-yl)methyl]-, ethyl ester, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

L17 ANSWER 5 OF 35 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 327175-55-3 CAPLUS
CN 2H-Furo[3,2-e]indole, 1,6,7,8-tetrahydro-2,2,4,5-tetramethyl-1-(4-methylphenyl)- (9CI) (CA INDEX NAME)



Cl. 14

IT **327175-38-2P**, 1,6,7,8-Tetrahydro-2-(iodomethyl)-2,4,5-trimethyl-2H-furo[3,2-e]indole-6-carboxaldehyde **327175-39-3P**, 1,6,7,8-Tetrahydro-2-(iodomethyl)-2,4,5-trimethyl-2H-furo[3,2-e]indole **327175-40-6P 327175-41-7P**, 1,6,7,8-Tetrahydro-2-(iodomethyl)-2,4,5,7,7-pentamethyl-2H-furo[3,2-e]indole **327175-47-3P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of hydrobenzofuran derivs. as inhibitors of lipid peroxide formation for preparation of various diseases)

RN 327175-38-2 CAPLUS
CN 6H-Furo[3,2-e]indole-6-carboxaldehyde, 1,2,7,8-tetrahydro-2-(iodomethyl)-2,4,5-trimethyl- (9CI) (CA INDEX NAME)



RN 327175-39-3 CAPLUS
CN 2H-Furo[3,2-e]indole, 1,6,7,8-tetrahydro-2-(iodomethyl)-2,4,5-trimethyl- (9CI) (CA INDEX NAME)



L17 ANSWER 5 OF 35 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 327175-40-6 CAPLUS
CN 6H-Furo[3,2-e]indole-6-carboxaldehyde, 1,2,7,8-tetrahydro-2-(iodomethyl)-2,4,5,7,7-pentamethyl- (9CI) (CA INDEX NAME)



RN 327175-41-7 CAPLUS
CN 2H-Furo[3,2-e]indole, 1,6,7,8-tetrahydro-2-(iodomethyl)-2,4,5,7,7-pentamethyl- (9CI) (CA INDEX NAME)



RN 327175-47-3 CAPLUS
CN 2H-Furo[3,2-e]indole, 2-(chloromethyl)-1,6,7,8-tetrahydro-2,4,5,7,7-pentamethyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 6 OF 35 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:152690 CAPLUS
DOCUMENT NUMBER: 134:193430
TITLE: Tricyclic dihydrobenzofuran derivatives, process for the preparation thereof and drugs
INVENTOR(S): Ohkawa, Shigenori; Hashimoto, Tadatoshi; Tsukamoto, Tetsuya
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 122 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001014384	A1	20010301	WO 2000-JP5523	20000818
W: AE, AG, AL, AM, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2000065949	A5	20010319	AU 2000-65949	20000818
JP 2001131179	A2	20010515	JP 2000-254231	20000818
EP 1211253	A1	20020605	EP 2000-953479	20000818
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				

PRIORITY APPLN. INFO.: JP 1999-234718 A 19990820
WO 2000-JP5523 W 20000818
OTHER SOURCE(S): MARPAT 134:193430
GI



I

AB Compds. represented by general formula (I; ring A is a nonarom. five- to seven-membered nitrogenous heterocycle which may be addnl. substituted; ring B is a benzene ring which is addnl. substituted; ring C is a dihydrofuran ring which may be addnl. substituted; and R is hydrogen or acyl) or salts thereof are prepared. Theses compds. exhibit excellent inhibitory activity against the formation of peroxylipid and are useful as inhibitors against the lipid peroxide formation and preventives for cerebral vascular disorders, head injuries, and degenerative nerve diseases such as Parkinson's disease and Alzheimer's disease, urination disorders, pollakiuria, and restenosis after percutaneous transluminal coronary angioplasty (PTCA). Thus, 309 mg 3,5,6,7-tetrahydro-2,4,8-trimethyl-2-[(4-phenylpiperidino)methyl]-2H-furo[2,3-f]indole-5-carboxaldehyde hydrochloride was dissolved in 5 mL MeOH, treated with 1 mL concd. HCl, and stirred at 60° under Ar for 1 h to give 77% 3,5,6,7-tetrahydro-2,4,8-trimethyl-2-[(4-phenylpiperidino)methyl]-2H-furo[2,3-f]indole (II) as an oil. II in vitro showed IC50 of 0.067 μM for inhibiting the peroxylipid formation in rat brain homogenate. Three tablet formulations contg. II were also prepd.

IT **327615-36-1P 327615-38-3P 327615-44-1P**
327615-51-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of tricyclic hydrobenzofuran derivs. as inhibitors for formation of lipid peroxide and drugs)

RN 327615-36-1 CAPLUS
CN 2H-Furo[2,3-f]indole, 5-acetyl-3,5,6,7-tetrahydro-2,2,4,6,8-pentamethyl- (9CI) (CA INDEX NAME)



RN 327615-38-3 CAPLUS
CN 2H-Furo[2,3-f]indole, 8-(1,1-dimethylethyl)-3,5,6,7-tetrahydro-2,2,4,6,6-pentamethyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 327615-44-1 CAPLUS
CN 2H-Furo[2,3-f]indole, 3,5,6,7-tetrahydro-2,4,8-trimethyl-2-[(4-phenyl-1-piperidinyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 327615-51-0 CAPLUS
CN 5H-Furo[2,3-f]indole-5-carboxaldehyde, 2-[[4-[(diphenylmethyl)amino]-1-piperidinyl]methyl]-2,3,6,7-tetrahydro-2,4,8-trimethyl- (9CI) (CA INDEX NAME)



IT **327615-37-2P 327615-39-4P 327615-40-7P**
327615-43-0P 327615-45-2P 327615-48-5P
327615-49-6P 327615-50-9P 327615-52-1P
327615-53-2P 327615-54-3P 327615-55-4P
327615-56-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of tricyclic hydrobenzofuran derivs. as inhibitors for formation of lipid peroxide and drugs)

RN 327615-37-2 CAPLUS
CN 2H-Furo[2,3-f]indole, 3,5,6,7-tetrahydro-2,2,4,6,8-pentamethyl- (9CI) (CA INDEX NAME)



RN 327615-39-4 CAPLUS
CN 5H-Furo[2,3-f]indole-5-carboxaldehyde, 2,3,6,7-tetrahydro-2-(hydroxymethyl)-2,4,8-trimethyl- (9CI) (CA INDEX NAME)



RN 327615-40-7 CAPLUS
CN 2H-Furo[2,3-f]indole, 8-(1,1-dimethylethyl)-5-(4-fluorobenzoyl)-3,5,6,7-tetrahydro-2,2,4,6,6-pentamethyl- (9CI) (CA INDEX NAME)



RN 327615-43-0 CAPLUS
CN 2H-Furo[2,3-f]indole, 3,5,6,7-tetrahydro-2,4,8-trimethyl-2-(1-piperidinylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 327615-45-2 CAPLUS
CN 2H-Furo[2,3-f]indole, 3,5,6,7-tetrahydro-2,4,8-trimethyl-2-[(4-phenyl-1-piperidinyl)methyl]- (9CI) (CA INDEX NAME)

L17 ANSWER 6 OF 35 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 327615-48-5 CAPLUS
CN 2H-Furo[2,3-f]indole, 3,5,6,7-tetrahydro-2,4,6,6,8-pentamethyl-2-[(4-phenyl-1-piperidinyl)methyl]- (9CI) (CA INDEX NAME)



RN 327615-49-6 CAPLUS
CN 2H-Furo[2,3-f]indole, 3,5,6,7-tetrahydro-2,4,8-trimethyl-2-[(3-phenyl-1-piperidinyl)methyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 327615-50-9 CAPLUS
CN 2H-Furo[2,3-f]indole, 3,5,6,7-tetrahydro-2,4,6,6,8-pentamethyl-2-[(1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

L17 ANSWER 6 OF 35 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



● HCl

RN 327615-52-1 CAPLUS
CN 4-Piperidinamine, N-(diphenylmethyl)-1-[(3,5,6,7-tetrahydro-2,4,8-trimethyl-2H-furo[2,3-f]indol-2-yl)methyl]-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl

RN 327615-53-2 CAPLUS
CN 4-Piperidinamine, N-(diphenylmethyl)-1-[(3,5,6,7-tetrahydro-2,4,6,6,8-pentamethyl-2H-furo[2,3-f]indol-2-yl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L17 ANSWER 6 OF 35 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 327615-54-3 CAPLUS
CN 2H-Furo[2,3-f]indole, 2-[[4-[3-(diphenylmethoxy)propyl]-1-piperidinyl]methyl]-3,5,6,7-tetrahydro-2,4,8-trimethyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 327615-55-4 CAPLUS
CN 2-Benzothiazolamine, N-methyl-N-[1-[(3,5,6,7-tetrahydro-2,4,6,6,8-pentamethyl-2H-furo[2,3-f]indol-2-yl)methyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 327615-56-5 CAPLUS
CN 2H-Furo[2,3-f]indole, 3,5,6,7-tetrahydro-2,2,4,8-tetramethyl-3-(4-methylphenyl)- (9CI) (CA INDEX NAME)



IT **327615-35-0P 327615-41-8P 327615-42-9P**
327615-46-3P 327615-47-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of tricyclic hydrobenzofuran derivs. as inhibitors for formation of lipid peroxide and drugs)

RN 327615-35-0 CAPLUS

L17 ANSWER 6 OF 35 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
CN 2H-Furo[2,3-f]indole, 3,5,6,7-tetrahydro-2,2,4,8-tetramethyl- (9CI) (CA INDEX NAME)



RN 327615-41-8 CAPLUS
CN 5H-Furo[2,3-f]indole-5-carboxaldehyde, 2,3,6,7-tetrahydro-2-(iodomethyl)-2,4,8-trimethyl- (9CI) (CA INDEX NAME)



RN 327615-42-9 CAPLUS
CN 2H-Furo[2,3-f]indole, 3,5,6,7-tetrahydro-2-(iodomethyl)-2,4,8-trimethyl- (9CI) (CA INDEX NAME)



RN 327615-46-3 CAPLUS
CN 5H-Furo[2,3-f]indole-5-carboxaldehyde, 2,3,6,7-tetrahydro-2-(iodomethyl)-2,4,6,6,8-pentamethyl- (9CI) (CA INDEX NAME)



L17 ANSWER 6 OF 35 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
RN 327615-47-4 CAPLUS
CN 2H-Furo[2,3-f]indole, 3,5,6,7-tetrahydro-2-(iodomethyl)-2,4,6,6,8-pentamethyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L17 ANSWER 7 OF 35 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2000:565896 CAPLUS
DOCUMENT NUMBER: 133:275848
TITLE: 1-[2-[(Heteroaryloxy)heteroaryl]carbamoyl]indolines: novel and selective 5-HT2C receptor inverse agonists with potential as antidepressant/Anxiolytic agents
AUTHOR(S): Bromidge, S. M.; Dabbs, S.; Davies, S.; Duckworth, D. M.; Forbes, I. T.; Jones, G. E.; Jones, J.; King, F. D.; Saunders, D. V.; Blackburn, T. P.; Holland, V.; Kennett, G. A.; Lightowler, S.; Middlemiss, D. N.; Riley, G. J.; Trail, B.; Wood, M. D.
CORPORATE SOURCE: Discovery Research, SmithKline Beecham Pharmaceuticals, Harlow, Essex, CM19 5AW, UK
SOURCE: Bioorganic & Medicinal Chemistry Letters (2000), 10(16), 1863-1866
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Bisaryl ethers have been identified with excellent 5-HT2C affinity and selectivity over both 5-HT2A and 5-HT2B receptors. Several compds. have potent oral activity in a centrally mediated pharmacodynamic model of 5-HT2C function and their potential as novel non-sedating anxiolytic and antidepressants is under investigation. Structure-activity relations are discussed.
IT **300554-18-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
([2-[(Heteroaryloxy)heteroaryl]carbamoyl]indolines as novel and selective 5-HT2C receptor inverse agonists with potential as antidepressant/anxiolytic agents)
RN 300554-18-1 CAPLUS
CN 6H-Furo[3,2-e]indole-6-carboxamide, 1,2,7,8-tetrahydro-N-[6-[(2-methyl-3-pyridinyl)oxy]-3-pyridinyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L17 ANSWER 8 OF 35 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1999:366062 CAPLUS
DOCUMENT NUMBER: 131:164975
TITLE: Structure-Activity Relationships for 5-Substituted 1-Phenylbenzimidazoles as Selective Inhibitors of the Platelet-Derived Growth Factor Receptor
AUTHOR(S): Palmer, Brian D.; Kraker, Alan J.; Hartl, Brian G.; Panopoulos, Athanasia D.; Panek, Robert L.; Batley, Brian L.; Lu, Gina H.; Trumpp-Kallmeyer, Susanne; Showalter, H. D. Hollis; Denny, William A.
CORPORATE SOURCE: Auckland Cancer Society Research Centre Faculty of Medicine and Health Sciences, The University of Auckland School of Medicine, Auckland, N. Z.
SOURCE: Journal of Medicinal Chemistry (1999), 42(13), 2373-2382
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 131:164975
AB Following an earlier discovery of 1-phenylbenzimidazoles as ATP-site inhibitors of the platelet-derived growth factor receptor (PDGFR), further structure-activity relationships for analogs (particularly 5-substituted derivs.) are reported. The data are consistent with a binding model (constructed from the homol.-modeled structure of the catalytic subunit of the PDGFR using protein kinase A as the template) in which the ligand binds in the relatively narrow ATP site, with the Ph ring pointing toward the interior of the pocket and the 5-position of the benzimidazole ring toward the mouth of the pocket. The narrow binding pocket allows a maximum torsion angle between the Ph and benzimidazole rings of about 40°, consistent with that calculated (43.6°) for the min.-energy conformation of the unsubstituted free ligand. The inactivity of 7- or 2'-substituted analogs is consistent with the greater torsion angle (and thus larger ligand cross-section) of such substituted analogs. There is substantial bulk tolerance for 5-substituents, which protrude out of the mouth of the hydrophobic pocket, with the most effective analogs being those bearing weak bases. On the basis of this model, 5-OR derivs. bearing cationic side chains were prepared as soluble analogs, and these showed sub-micromolar potencies against the isolated PDGFR enzyme. They were also moderately effective inhibitors of autophosphorylation of PDGFR in rat aortic vascular smooth muscle cells, with IC50s in the range 0.1-1 μM.
IT **238426-27-2P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(structure-activity relationships for 5-substituted phenylbenzimidazoles as selective inhibitors of platelet-derived growth factor receptor)
RN 238426-27-2 CAPLUS
CN 3H-Furo[3,2-e]benzimidazole, 7,8-dihydro-7-methyl-3-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)

L17 ANSWER 8 OF 35 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



● HCl

REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L17 ANSWER 9 OF 35 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1997:635175 CAPLUS
DOCUMENT NUMBER: 127:318730
TITLE: The synthesis of phenylhydrazines from bis(2,2,2-trichloroethyl) azodicarboxylates and electron-rich arenes
AUTHOR(S): Dufresne, Claude; Leblanc, Yves; Berthelette, Carl; Mccooeye, Chris
CORPORATE SOURCE: Merck Frosst Centre for Therapeutic Research, Pointe-Claire-Dorval, QC, H9R 4P8, Can.
SOURCE: Synthetic Communications (1997), 27(20), 3613-3624
CODEN: SYNCAV; ISSN: 0039-7911
PUBLISHER: Dekker
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 127:318730
AB Hydrazides from the title process were deprotected in 44-76% yields by treating with Zn dust in MeOH using NH4OAc as a buffer to give the correesponding hydrazines. Two of the novel hydrazines were converted to indoles.
IT **197590-49-1P 197590-50-4P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(synthesis of phenylhydrazines by deprotection of hydrazides)
RN 197590-49-1 CAPLUS
CN 2H-Furo[3,2-e]indole-8-acetic acid, 1,6-dihydro-7-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 197590-50-4 CAPLUS
CN 2H-Furo[2,3-f]indole-7-acetic acid, 3,5-dihydro-6-methyl-, methyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 9 OF 35 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

L17 ANSWER 10 OF 35 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1997:618091 CAPLUS
DOCUMENT NUMBER: 127:278142
TITLE: Preparation of tricyclic compounds with binding affinity for melatonin receptor
INVENTOR(S): Ohkawa, Shigenori; Uchikawa, Osamu; Fukatsu, Kohji; Miyamoto, Masaomi
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 269 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9732871	A1	19970912	WO 1997-JP677	19970305
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GH, HU, IL, IS, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2241666	AA	19970912	CA 1997-2241666	19970305
AU 9722318	A1	19970922	AU 1997-22318	19970305
AU 706610	B2	19990617		
EP 885210	A1	19981223	EP 1997-905450	19970305
EP 885210	B1	20020612		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
CN 1212691	A	19990331	CN 1997-192700	19970305
EP 1199304	A1	20020424	EP 2001-119552	19970305
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
AT 219071	E	20020615	AT 1997-905450	19970305
PT 885210	T	20020930	PT 1997-905450	19970305
ES 2175350	T3	20021116	ES 1997-905450	19970305
CZ 291626	B6	20030416	CZ 1998-2775	19970305
US 6034239	A	20000307	US 1997-812168	19970306
JP 10287665	A2	19981027	JP 1997-52175	19970307
JP 2884153	B2	19990419		
JP 11152281	A2	19990608	JP 1998-268110	19970307
NO 9803970	A	19980828	NO 1998-3970	19980828
US 6218429	B1	20010417	US 1999-309519	19990510

PRIORITY APPLN. INFO.: JP 1996-51491 A 19960308
JP 1996-183667 A 19960712
JP 1997-29185 A 19970213
US 1996-13733P P 19960320
US 1996-23090P P 19960725
EP 1997-905450 A3 19970305
WO 1997-JP677 W 19970305
US 1997-812168 A3 19970306
JP 1997-52175 A3 19970307

OTHER SOURCE(S): MARPAT 127:278142
GI

L17 ANSWER 10 OF 35 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



I



II

AB The title compds. [I; R1 = (un)substituted alkyl, NH2, heterocyclyl; R2 = H, (un)substituted alkyl; R3 = H, (un)substituted alkyl, heterocyclyl; X = CHR4, NR4, O, S (wherein R4 = H, alkyl); Y = C, CH, N (when X = CH2, Y = C, CH); ring A = (un)substituted 5-7 membered O-containing heterocyclyl; ring B = (un)substituted benzene ring; m = 1-4; n = 0-2], useful as regulating agent of circadian rhythm, sleep-awake rhythm and time zone change syndrome, and for the treatment of sleep disorders, were prepared and formulated. Thus, treatment of 2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethylamine.HBr with Ac2O and 1N NaOH in THF afforded 66% II which showed IC50 of 0.28 nM against 2-[125I]iodomelatonin binding.
IT **196597-53-2P 196597-56-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of tricyclic compds. with binding affinity for melatonin receptor)
RN 196597-53-2 CAPLUS
CN Propanamide, N-[2-(6-formyl-1,6,7,8-tetrahydro-2H-furo[3,2-e]indol-8-yl)ethyl]- (9CI) (CA INDEX NAME)



RN 196597-56-5 CAPLUS
CN Butanamide, N-[2-(6-formyl-1,6,7,8-tetrahydro-2H-furo[3,2-e]indol-8-yl)ethyl]- (9CI) (CA INDEX NAME)

L17 ANSWER 10 OF 35 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



IT **196597-54-3P 196597-55-4P 196597-57-6P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of tricyclic compds. with binding affinity for melatonin receptor)

RN 196597-54-3 CAPLUS
CN Propanamide, N-[2-(1,6,7,8-tetrahydro-2H-furo[3,2-e]indol-8-yl)ethyl]- (9CI) (CA INDEX NAME)



RN 196597-55-4 CAPLUS
CN Propanamide, N-[2-(1,6,7,8-tetrahydro-2H-furo[3,2-e]indol-8-yl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L17 ANSWER 10 OF 35 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 196597-57-6 CAPLUS
CN Butanamide, N-[2-(1,6,7,8-tetrahydro-2H-furo[3,2-e]indol-8-yl)ethyl]- (9CI) (CA INDEX NAME)



L17 ANSWER 11 OF 35 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1997:262324 CAPLUS
DOCUMENT NUMBER: 126:251157
TITLE: Preparation of heterocyclylbiphenyl(thio)amide and -biphenylethan(thi)one derivatives as 5-HT1D receptor antagonists.
INVENTOR(S): Gaster, Laramie Mary
PATENT ASSIGNEE(S): Smithkline Beecham Plc, UK; Gaster, Laramie Mary
SOURCE: PCT Int. Appl., 30 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9707120	A1	19970227	WO 1996-EP3511	19960806
W: JP, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
JP 11511156	T2	19990928	JP 1996-508914	19960806
EP 1019412	A1	20000719	EP 1996-929225	19960806
R: BE, CH, DE, ES, FR, GB, IT, LI, NL				
US 5972935	A	19991026	US 1998-11338	19980424

PRIORITY APPLN. INFO.: GB 1995-16456 A 19950811
GB 1996-6632 A 19960329
GB 1996-6633 A 19960329
WO 1996-EP3511 W 19960806
OTHER SOURCE(S): MARPAT 126:251157
GI



I

AB Title compds. [I; R = substituted biphenylyl; R6 = H, alkyl; R7 = alkyl, alkoxy, halo; R6R7 = bridging group; R18, R19 = H, alkyl; R20, R21 = H, alkyl, aralkyl; NR20R21 = (substituted) 5-7 membered ring; m = 0-4; B = O, S; D = N, C, CH; Q = atoms to form a (substituted) 5-7 membered heterocyclic ring], were prepared as 5-HT1D receptor antagonists (no data). Thus, 2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-carboxylic acid was refluxed with SOCl2 and the residue was stirred with 4-(2-dimethylaminoethyl)-2,3,6,7,8,9-hexahydro-4H-pyrido[2,3-g][1,4]benzoxazine (preparation given) and Et3N in CH2Cl2 to give 4-(2-dimethylaminoethyl)-2,3,6,7,8,9-hexahydro-6-[2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-carbonyl]-4H-pyrido[2,3-g][1,4]benzoxazine.

IT **188592-76-9P 188592-77-0P 188592-79-2P 188592-80-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of heterocyclylbiphenyl(thio)amide and -biphenylethan(thi)one derivs. as 5-HT1D receptor antagonists)

RN 188592-76-9 CAPLUS
CN Furo[2,3-g]quinoline-3-ethanamine, 2,3,5,6,7,8-hexahydro-N,N-dimethyl-5-[[2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)[1,1'-biphenyl]-4-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 188592-77-0 CAPLUS
CN Furo[2,3-g]quinoline-3-ethanamine, 2,3,5,6,7,8-hexahydro-N,N-dimethyl-5-[[2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)[1,1'-biphenyl]-4-yl]carbonyl]-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 188592-76-9
CMF C32 H34 N4 O3

L17 ANSWER 11 OF 35 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



CM 2

CRN 144-62-7
CMF C2 H2 O4

RN 188592-79-2 CAPLUS
CN 2H-Furo[2,3-f]indole-3-ethanamine, 3,5,6,7-tetrahydro-N,N-dimethyl-5-[[2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)[1,1'-biphenyl]-4-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 188592-80-5 CAPLUS
CN 2H-Furo[2,3-f]indole-3-ethanamine, 3,5,6,7-tetrahydro-N,N-dimethyl-5-[[2'-

L17 ANSWER 11 OF 35 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)[1,1'-biphenyl]-4-yl]carbonyl]-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 188592-79-2
CMF C31 H32 N4 O3



CM 2

CRN 144-62-7
CMF C2 H2 O4

IT **188593-00-2P 188593-02-4P 188593-11-5P 188593-13-7P 188593-15-9P 188593-17-1P 188593-19-3P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of heterocyclylbiphenyl(thio)amide and -biphenylethan(thi)one derivs. as 5-HT1D receptor antagonists)

RN 188593-00-2 CAPLUS
CN Furo[2,3-g]quinoline-3-ethanamine, 2,3-dihydro-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 188593-02-4 CAPLUS
CN Furo[2,3-g]quinoline-3-ethanamine, 2,3,5,6,7,8-hexahydro-N,N-dimethyl- (9CI) (CA INDEX NAME)

L17 ANSWER 11 OF 35 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 188593-11-5 CAPLUS
CN 2H-Furo[2,3-f]indole-3-acetic acid, 5-acetyl-3,5,6,7-tetrahydro-, methyl ester (9CI) (CA INDEX NAME)



RN 188593-13-7 CAPLUS
CN 2H-Furo[2,3-f]indole-3-acetic acid, 3,5,6,7-tetrahydro-5-[(phenylmethoxy)carbonyl]- (9CI) (CA INDEX NAME)



RN 188593-15-9 CAPLUS
CN 5H-Furo[2,3-f]indole-5-carboxylic acid, 3-[2-(dimethylamino)-2-oxoethyl]-2,3,6,7-tetrahydro-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 188593-17-1 CAPLUS
CN 2H-Furo[2,3-f]indole-3-acetamide, 3,5,6,7-tetrahydro-N,N-dimethyl- (9CI) (CA INDEX NAME)

L17 ANSWER 11 OF 35 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 188593-19-3 CAPLUS
CN 2H-Furo[2,3-f]indole-3-ethanamine, 3,5,6,7-tetrahydro-N,N-dimethyl- (9CI) (CA INDEX NAME)



L17 ANSWER 12 OF 35 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1997:199838 CAPLUS
DOCUMENT NUMBER: 126:293012
TITLE: Mass spectral study of isomeric benzoxazolinones by electron ionization
AUTHOR(S): Prabhakar, S.; Gawali, B. B.; Bhalerao, U. T.; Vairamani, M.
CORPORATE SOURCE: Indian Institute of Chemical Technology, Hyderabad, 500 007, India
SOURCE: European Mass Spectrometry (1997), 3(1), 49-54
CODEN: EMSPFW; ISSN: 1356-1049
PUBLISHER: IM Publications
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



AB The electron impact mass spectra of isomeric dihydrofurobenzoxazolinones, I (X = O, Y = NH; X = NH, Y = O) and II, hydroxy(2-methyl-2-propenyl)benzoxazolinones III and (2-methyl-2-propenyloxy)benzoxazolinones IV are studied. The mass spectra of I and II show differences in the relative abundance of an ion at m/z 163. A mechanism involving the heteroatom of the benzoxazolinone ring which is para to the oxygen of the dihydrofuran ring has been proposed to explain the results. The mass spectra and collision-induced dissociation spectra of mol. ions of III are similar to those of I, resp., suggesting the rearrangement of III to I, resp., in the source of the mass spectrometer. The fragmentation of IV supports the proposition of dihydrofuran ring opening in I and II. The fragmentation of IV is different in comparison to III, suggesting that IV do not rearrange to III, resp., either before or after ionization.
IT **149036-29-3 149274-23-7**
RL: PRP (Properties)
(electron impact mass spectra of benzoxazolinones)
RN 149036-29-3 CAPLUS
CN Furo[2,3-g]benzoxazol-2(3H)-one, 7,8-dihydro-7,7-dimethyl- (9CI) (CA INDEX NAME)

L17 ANSWER 12 OF 35 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 149274-23-7 CAPLUS
CN Furo[3,2-f]benzoxazol-2(1H)-one, 6,7-dihydro-6,6-dimethyl- (9CI) (CA INDEX NAME)



L17 ANSWER 13 OF 35 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1997:8083 CAPLUS
DOCUMENT NUMBER: 126:117857
TITLE: Synthesis of a 1,3,4,5-tetrahydrobenz[cd]indole via the vicarious nucleophilic substitution of hydrogen
AUTHOR(S): Makosza, Mieczyslaw; Stalewski, Jacek; Wojciechowski, Krzysztof; Danikiewicz, Witold
CORPORATE SOURCE: Inst. Organic Chemistry, Polish Academy Sciences, Warsaw, 01-224, Pol.
SOURCE: Tetrahedron (1997), 53(1), 193-214
CODEN: TETRAB; ISSN: 0040-4020
PUBLISHER: Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



AB Two approaches to synthesis of 6-methoxy-1,3,4,5-tetrahydrobenz[cd]indol-4-amine (I) were developed. The required indole precursor of the tricyclic system was prepared via a vicarious nucleophilic substitution reaction, but attempts to execute the C ring closure failed. Another strategy, based on elaboration of a vicarious nucleophilic substitution product to a tetrahydronaphthalene system followed with formation of the fused pyrrole ring, proved successful.
IT **186263-52-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of tetrahydrobenz[cd]indole via vicarious nucleophilic substitution)
RN 186263-52-5 CAPLUS
CN 2H-Furo[3,2-e]indole, 1,6-dihydro-2-(iodomethyl)-8-[(4-methylphenyl)sulfonyl]-6-(methylsulfonyl)- (9CI) (CA INDEX NAME)

L17 ANSWER 13 OF 35 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



REFERENCE COUNT: 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 14 OF 35 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1996:427209 CAPLUS
DOCUMENT NUMBER: 125:195464
TITLE: A convenient modification of the Gassman oxindole synthesis
AUTHOR(S): Wright, Stephen W.; McClure, Lester D.; Hageman, David L.
CORPORATE SOURCE: Pfizer Central Research, Groton, CT, 06340, USA
SOURCE: Tetrahedron Letters (1996), 37(27), 4631-4634
CODEN: TELEAY; ISSN: 0040-4039
PUBLISHER: Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English

AB A modification of the Gassman oxindole synthesis is described that proceeds from anilines XC6H4NH2 (X = H, 4-MeO, 2-Me, 3-MeS, etc.) and Et (methylsulfinyl)acetate, using oxalyl chloride to activate the sulfoxide to facilitate the formation of the key N - S bonded intermediate. This procedure is particularly convenient for reactions carried out on smaller scales and for anilines that are susceptible to electrophilic halogenation.

IT **103113-43-5P 181059-70-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(Gassman oxindole synthesis from anilines and Et (methylsulfinyl)acetate)

RN 103113-43-5 CAPLUS
CN 6H-Furo[2,3-f]indol-6-one, 5-ethyl-2,3,5,7-tetrahydro- (9CI) (CA INDEX NAME)



RN 181059-70-1 CAPLUS
CN 6H-Furo[2,3-f]indol-6-one, 2,3,5,7-tetrahydro-7-(methylthio)- (9CI) (CA INDEX NAME)



L17 ANSWER 15 OF 35 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1995:998396 CAPLUS
DOCUMENT NUMBER: 124:176069
TITLE: Preparation of tricyclic compounds as 5-HT2c and 5-HT2b antagonists.
INVENTOR(S): King, Francis David; Ham, Peter; Forbes, Ian Thomson; Jones, Graham Elgin
PATENT ASSIGNEE(S): Smithkline Beecham P.L.C., UK
SOURCE: PCT Int. Appl., 31 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9529177	A1	19951102	WO 1995-EP901	19950309
W: JP, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 757687	A1	19970212	EP 1995-911322	19950309
R: BE, CH, DE, FR, GB, IT, LI, NL				
JP 09512025	T2	19971202	JP 1995-527301	19950309

PRIORITY APPLN. INFO.: GB 1994-8097 19940423
GB 1994-10506 19940525
WO 1995-EP901 19950309
OTHER SOURCE(S): MARPAT 124:176069
GI



AB Title compds. (I; Q = Ph, quinoline, isoquinoline residue, 5- or 6-membered aromatic heterocyclic ring containing ≤3 heteroatoms selected from N, O, S; J = bicyclic aromatic or partially saturated ring system; R1, R2 = H, halo, OH, O alkyl optionally substituted by ≥1 halo; R4 = H, alkyl, alkylthio, halo, nitro, cyano, CF3, NR8R9, CO2R12, CONR12, OR12; R8, R9, R12 = H, alkyl, aralkyl; R5, R13, R14 = H, alkyl; n = 2, 3; provided that P ≠ hetercyclic group when J = benzothiophene ring), were prepared as serotonin antagonists (no data). Thus, nicotinoyl azide was refluxed 1.75 h in PhMe; 2,3-dihydro-1H-pyrrolo[2,3-g]quinoline in CH2Cl2 was added and the mixture was stirred overnight to give 1-(3-pyridylcarbamoyl)-2,3-dihydro-1H-pyrrolo[2,3-g]quinoline.

IT **173669-22-2P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of tricyclic compds. as 5-HT2c and 5-HT2b antagonists)

RN 173669-22-2 CAPLUS
CN 5H-Furo[2,3-f]indole-5-carboxamide, 2,3,6,7-tetrahydro-2,2-dimethyl-N-3-

L17 ANSWER 15 OF 35 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
pyridinyl- (9CI) (CA INDEX NAME)



IT **173669-39-1P 173669-40-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of tricyclic compds. as 5-HT2c and 5-HT2b antagonists)

RN 173669-39-1 CAPLUS
CN 2H-Furo[2,3-f]indole, 3,5,6,7-tetrahydro-2,2-dimethyl-5-(trifluoroacetyl)- (9CI) (CA INDEX NAME)



RN 173669-40-4 CAPLUS
CN 2H-Furo[2,3-f]indole, 3,5,6,7-tetrahydro-2,2-dimethyl- (9CI) (CA INDEX NAME)



L17 ANSWER 16 OF 35 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1995:313308 CAPLUS
DOCUMENT NUMBER: 122:133042
TITLE: Synthesis and antimicrobial activity of dihydrofurobenzoxazolin-2(3H)-ones and their derivatives
AUTHOR(S): Bhalerao, U. T.; Gawali, B. B.; Annapurna, J.
CORPORATE SOURCE: Org. Div. II, Indian Inst. Chem. Tech., Hyderabad, India
SOURCE: Arzneimittel-Forschung (1994), 44(9), 1077-9
CODEN: ARZNAD; ISSN: 0004-4172
PUBLISHER: Cantor
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I



II

AB A series of dihydrofurobenzoxazolin-2(3H)-ones and their derivs. were synthesized. The in vitro activity of these compds. was investigated against Gram-pos. and Gram-neg. bacteria and also against Candida albicans. Furo[2,3-g]benzoxazolin-2(3H)-one I proved to be more potent than furo[2,3-f]benzoxazolin-2(3H)-one II (X = NH, Y = O). Compound II (X = O, Y = NH) also showed significant activity against all the microbes tested. Compds. II (X = O, Y = NAc, X = NAc, Y = O) were more effective against Gram-pos. bacteria than Gram-neg. bacteria but inactive against C. albicans.

IT **149274-23-7P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(synthesis and antimicrobial activity of dihydrofurobenzoxazolinones and their deriva.)

RN 149274-23-7 CAPLUS
CN Furo[3,2-f]benzoxazol-2(1H)-one, 6,7-dihydro-6,6-dimethyl- (9CI) (CA INDEX NAME)



IT **149036-29-3P 160984-76-9P 160984-77-0P**

L17 ANSWER 16 OF 35 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

160984-78-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(synthesis and antimicrobial activity of dihydrofurobenzoxazolinones and their derivs.)

RN 149036-29-3 CAPLUS
CN Furo[2,3-g]benzoxazol-2(3H)-one, 7,8-dihydro-7,7-dimethyl- (9CI) (CA INDEX NAME)



RN 160984-76-9 CAPLUS
CN Furo[3,2-f]benzoxazol-2(1H)-one, 1-acetyl-6,7-dihydro-6,6-dimethyl- (9CI) (CA INDEX NAME)



RN 160984-77-0 CAPLUS
CN Furo[3,2-f]benzoxazol-2(1H)-one, 6,7-dihydro-6,6-dimethyl-1-(2-methyl-2-propenyl)- (9CI) (CA INDEX NAME)



RN 160984-78-1 CAPLUS
CN Furo[3,2-f]benzoxazol-2(1H)-one, 6,7-dihydro-6,6-dimethyl-1-(phenylmethyl)- (9CI) (CA INDEX NAME)

L17 ANSWER 16 OF 35 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



L17 ANSWER 17 OF 35 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1994:655734 CAPLUS
DOCUMENT NUMBER: 121:255734
TITLE: Studies on Claisen rearrangement of substituted 5-allyoxyindoles, furoindole synthesis and their antimicrobial activity
AUTHOR(S): Gadaginamath, G. S.; Joshi, R. G.; Kamat, A. G.
CORPORATE SOURCE: Dep. Chem., Karnatak Univ., Dharwad, 580 003, India
SOURCE: Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry (1994), 33B(4), 400-4
CODEN: IJSBDB; ISSN: 0376-4699
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Claisen rearrangement of 3-carbethoxy/acetyl-5-allyloxyindoles, obtained by the reaction of 5-hydroxyindoles with allyl bromide by heating in boiling N,N-diethylaniline results in exclusive formation of 4-allyl-3-carbethoxy/acetyl-5-hydroxy-2-methylindoles. It indicates the preferential migration of allyl group to the C-4 position in spite of the steric influence of the C-3 carbethoxy/acetyl group. Further, cyclization of 4-allyl-6-bromo-1-butyl-1-carbethoxy-5-hydroxy-2-methylindole using concentrated H2SO4 yields 8-bromo-6-butyl-4-carboxy-2,5-dimethyl-2,3-dihydrofuro[3,2-e]indole. All the new compds. have been screened for their antibacterial and antifungal activities.

IT **158502-53-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(Claisen rearrangement of substituted 5-allyoxyindoles, furoindole synthesis and their bactericidal and fungicidal activities)

RN 158502-53-5 CAPLUS
CN 2H-Furo[3,2-e]indole-8-carboxylic acid, 4-bromo-6-butyl-1,6-dihydro-2,7-dimethyl- (9CI) (CA INDEX NAME)



L17 ANSWER 18 OF 35 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1993:495391 CAPLUS
DOCUMENT NUMBER: 119:95391
TITLE: A new synthesis of linear and angular dihydrofurobenzoxazolin-2(3H)-ones
AUTHOR(S): Bhalerao, U. T.; Gawali, B. B.
CORPORATE SOURCE: Indian Inst. Chem. Technol., Hyderabad, 500 007, India
SOURCE: Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry (1993), 32B(4), 413-17
CODEN: IJSBDB; ISSN: 0376-4699
DOCUMENT TYPE: Journal
LANGUAGE: English

AB 6,6-Dimethyl-6,7-dihydrofuro[3,2-f]benzoxazolin-2(3H)-one and 7,7-dimethyl-7,8-dihydrofuro[2,3-g]benzoxazolin-2(3H)-one have been synthesized through Curtius and Claisen rearrangements.

IT **149036-29-3P 149274-23-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, from dihydrobenzoate)

RN 149036-29-3 CAPLUS
CN Furo[2,3-g]benzoxazol-2(3H)-one, 7,8-dihydro-7,7-dimethyl- (9CI) (CA INDEX NAME)



RN 149274-23-7 CAPLUS
CN Furo[3,2-f]benzoxazol-2(1H)-one, 6,7-dihydro-6,6-dimethyl- (9CI) (CA INDEX NAME)



L17 ANSWER 19 OF 35 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1993:472603 CAPLUS
DOCUMENT NUMBER: 119:72603
TITLE: Preparation of benzimidazole derivatives as agrochemical fungicides
INVENTOR(S): Enomoto, Masayuki; Takahashi, Junya; Kusaba, Tomoyuki;
Sugano, Masayo; Matsunaga, Rei; Tamaoki, Masahiro
PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 10 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 05001068	A2	19930108	JP 1991-148550	19910620

PRIORITY APPLN. INFO.: JP 1991-148550 19910620
GI


I


II

AB Benzimidazole derivs. [I; R = cyano, H2NCS] are prepared K2CO3 was added to
a solution of 0.6 g cyano compound II (R1 = H) in MeCN, the mixture was refluxed,
0.4 g Me2NSO2Cl was added and the mixture was refluxed to give 0.48 g sulfonamide II (R1 = Me2NSO2 at 1- or 3-position), which controlled Phytophthora capsici and Phytophthora infestans at 3 ppm, vs. no control with manzeb.
IT **148515-23-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, in preparation of agrochem. fungicide)
RN 148515-23-5 CAPLUS
CN 1H-Furo[3,2-e]benzimidazole, 7,7,8,8-tetrafluoro-7,8-dihydro-2-(trichloromethyl)- (9CI) (CA INDEX NAME)

L17 ANSWER 19 OF 35 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



IT **148851-09-6P 148887-12-1P**
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as agrochem. fungicide)
RN 148851-09-6 CAPLUS
CN Furo[3,2-e]benzimidazolesulfonamide, 2-cyano-7,7,8,8-tetrafluoro-7,8-dihydro-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 148887-12-1 CAPLUS
CN Furo[3,2-e]benzimidazole-2-carbothioamide, 1(or 3)-[(dimethylamino)sulfonyl]-7,7,8,8-tetrafluoro-7,8-dihydro- (9CI) (CA INDEX NAME)

L17 ANSWER 19 OF 35 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



IT **148515-22-4**
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, in preparation of agrochem. fungicide)
RN 148515-22-4 CAPLUS
CN 1H-Furo[3,2-e]benzimidazole-2-carbonitrile, 7,7,8,8-tetrafluoro-7,8-dihydro- (9CI) (CA INDEX NAME)



L17 ANSWER 20 OF 35 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1993:254931 CAPLUS
DOCUMENT NUMBER: 118:254931
TITLE: Benzimidazole derivatives, a method for producing the same, agricultural and horticultural fungicides containing the same as an active ingredient and intermediate compounds thereof
INVENTOR(S): Enomoto, Masayuki; Takahashi, Junya; Kusaba, Tomoyuki;
Sugano, Masayo; Matsunaga, Rei; Tamaki, Masahiro
PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd., Japan
SOURCE: Eur. Pat. Appl., 53 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 517476	A2	19921209	EP 1992-305030	19920602
EP 517476	A3	19930210		
EP 517476	B1	19971008		
R: AT, BE, CH, DE, ES, FR, GB, IT, LI, LU, NL				
AU 9216348	A1	19921210	AU 1992-16348	19920518
AU 648665	B2	19940428		
CA 2069555	AA	19921204	CA 1992-2069555	19920526
JP 05301860	A2	19931116	JP 1992-138674	19920529
JP 3301111	B2	20020715		
PL 169678	B1	19960830	PL 1992-294754	19920601
US 5310747	A	19940510	US 1992-894007	19920602
RU 2036195	C1	19950527	RU 1992-5052001	19920602
ES 2107505	T3	19971201	ES 1992-305030	19920602
HU 61553	A2	19930128	HU 1992-1862	19920603
BR 9202122	A	19930202	BR 1992-2122	19920603
US 5472974	A	19951205	US 1993-175763	19931230
US 5395952	A	19950307	US 1994-179123	19940110

PRIORITY APPLN. INFO.: JP 1991-131101 A 19910603
JP 1991-134048 A 19910605
JP 1991-184442 A 19910724
JP 1992-39302 A 19920226
US 1992-894007 A3 19920602
OTHER SOURCE(S): MARPAT 118:254931
GI


I


II


III


IV

L17 ANSWER 20 OF 35 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

AB The agricultural and horticultural fungicidal substituted benzimidazoles I (R = cyano, thiocarbamoyl; R1 = alkyl, NR2R3, R2, R3 = alkyl, phenylalkyl, alkenyl, alkynyl; R2R3 = alkylene which may include a hetero atom; X = H, halo; Z = group consisting of one oxygen atom or two nonadjacent oxygen atoms, CF2, and any one of single bond, CF2, CFH, CFCl and CH2 groups and forms a 5- or 6-membered ring) were prepared from a corresponding 2-cyanobenzimidazole and a sulfamoyl chloride derivative Thus, the cyanobenzimidazole II (R4 = H) prepared in 6 steps from the anilide III via cyclization of the diamine IV with Cl3CC(:NH)OMe, was treated with Me2NSO2Cl in MeCN containing K2CO3 to give II (R4 = Me2NSO2). At 25 ppm I (R = cyano, R1 = Me2N, X = H, Z = CF2CF2O) controlled tomato blight by 92.5%.

IT **147610-38-6P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, with ammonia)

RN 147610-38-6 CAPLUS

CN 1H-Furo[2,3-f]benzimidazole, 6,6,7,7-tetrafluoro-6,7-dihydro-2-(trichloromethyl)- (9CI) (CA INDEX NAME)



IT **147610-30-8P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and sulfamoylation of)

RN 147610-30-8 CAPLUS

CN 1H-Furo[2,3-f]benzimidazole-2-carbonitrile, 6,6,7,7-tetrafluoro-6,7-dihydro- (9CI) (CA INDEX NAME)



IT **147369-24-2P 147369-25-3P 147369-26-4P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 147369-24-2 CAPLUS

CN 1H-Furo[2,3-f]benzimidazolesulfonamide, 2-cyano-6,6,7,7-tetrafluoro-6,7-

L17 ANSWER 20 OF 35 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



L17 ANSWER 20 OF 35 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
dihydro-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 147369-25-3 CAPLUS

CN 1H-Furo[2,3-f]benzimidazolesulfonamide, 2-cyano-N-ethyl-6,6,7,7-tetrafluoro-6,7-dihydro-N-methyl- (9CI) (CA INDEX NAME)



RN 147369-26-4 CAPLUS

CN 1H-Furo[2,3-f]benzimidazole-2-carbothioamide, 1(or 3)-[(dimethylamino)sulfonyl]-6,6,7,7-tetrafluoro-6,7-dihydro- (9CI) (CA INDEX NAME)

L17 ANSWER 21 OF 35 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1992:633889 CAPLUS

DOCUMENT NUMBER: 117:233889

TITLE: Formation of a novel thiopyranoindole ring system

AUTHOR(S): Hutchinson, John H.; McEachern, Ernie J.; Scheigetz, John; Macdonald, Dwight; Therien, Michel

CORPORATE SOURCE: Merck Frosst Cent. Ther. Res., Pointe Claire-Dorval, QC, H9R 4P8, Can.

SOURCE: Tetrahedron Letters (1992), 33(33), 4713-16
CODEN: TELEAY; ISSN: 0040-4039

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 117:233889

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The novel thiopyrano[2,3,4-c,d]indole ring system, e.g. I, has been prepared from a substituted indole, e.g. II, by intramol. cyclization of a Me3CS group onto an allyl substituent in allylindoles, e.g. III. The reaction occurs in high yield under the influence of protic acids, Lewis acids or electrophiles (Br2, I2, Hg(OAc)2).

IT **144397-05-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 144397-05-7 CAPLUS

CN 2H-Furo[3,2-e]indole-7-carboxylic acid, 6-[(4-chlorophenyl)methyl]-8-[(1,1-dimethylethyl)thio]-1,6-dihydro-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)



L17 ANSWER 22 OF 35 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1992:174023 CAPLUS
DOCUMENT NUMBER: 116:174023
TITLE: The synthesis of pyrano[3,2-e]indoles and pyrano[2,3-f]indoles as rotationally restricted phenolic analogs of the neurotransmitter serotonin
AUTHOR(S): Macro, John E.; Ryan, Kevin; Newman, Michael E.
CORPORATE SOURCE: Cent. Res. Div., Pfizer Inc., Groton, CT, 06340, USA
SOURCE: Tetrahedron (1992), 48(6), 1039-52
CODEN: TETRAB; ISSN: 0040-4020
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



AB The synthesis of two rotationally restricted phenolic analogs I and II (R = CH2CH2NMe2) of the neurotransmitter serotonin have been accomplished. The syntheses of dihydropyranoindoles I and II (R = H), which formed the template for these targets, are outlined. These novel fused-indoles represent rotationally restricted phenolic analogs of 5-hydroxyindole. The reaction sequence of Claisen rearrangement of 3-Me,4-(NO2)C6H3OCH2CH:CH2, followed by olefin hydroxylation, and intramol. Mitsunobu reaction was used to form the fused dihydropyran rings.
IT **140427-42-5P 140427-43-6P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 140427-42-5 CAPLUS
CN 2H-Furo[3,2-e]indole, 3,6-dihydro-2-methyl- (9CI) (CA INDEX NAME)



RN 140427-43-6 CAPLUS
CN 2H-Furo[2,3-f]indole, 3,5-dihydro-2-methyl- (9CI) (CA INDEX NAME)

L17 ANSWER 22 OF 35 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



L17 ANSWER 23 OF 35 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1992:59248 CAPLUS
DOCUMENT NUMBER: 116:59248
TITLE: Studies on uricosuric diuretics. II. Substituted 7,8-dihydrofuro[2,3-g]-1,2-benzisoxazole-7-carboxylic acids and 7,8-dihydrofuro[2,3-g]benzoxazole-7-carboxylic acids
AUTHOR(S): Sato, Haruhiko; Dan, Takashi; Onuma, Etsuro; Tanaka, Haruko; Aoki, Bunya; Koga, Hiroshi
CORPORATE SOURCE: Explor. Res. Lab., Chugai Pharm. Co., Ltd., Gotemba, 412, Japan
SOURCE: Chemical & Pharmaceutical Bulletin (1991), 39(7), 1760-72
CODEN: CPBTAL; ISSN: 0009-2363
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



AB A series of substituted dihydrofurobenzisoxazole- and -benzoxazolecarboxylic acids, e.g., I (Ar = substituted Ph, 2-thienyl, 3-pyridyl; R = H, Cl; R1 = H, Me, Br, Cl), II (R2 = H, Me, F; R3, R4 = H, Cl), were synthesized and evaluated for uricosuric and diuretic activities in rats. Many of the benzisoxazoles I showed uricosuric and only weak diuretic activities, whereas the benzoxazoles II exhibited potent diuretic activities with little effect on urate excretion. Among these compds., I (Ar = Ph; R = H, R1 = Cl) (AA-193) was found to be a potent uricosuric agent without diuretic activity and was selected for further development.
IT **114990-78-2P 136742-00-2P 136742-02-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and Jones oxidation of)
RN 114990-78-2 CAPLUS
CN Furo[2,3-g]benzoxazole-7-methanol, 4,5-dichloro-7,8-dihydro-2-phenyl- (9CI) (CA INDEX NAME)

L17 ANSWER 23 OF 35 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 136742-00-2 CAPLUS
CN Furo[2,3-g]benzoxazole-7-methanol, 4,5-dichloro-2-(2-fluorophenyl)-7,8-dihydro- (9CI) (CA INDEX NAME)



RN 136742-02-4 CAPLUS
CN Furo[2,3-g]benzoxazole-7-methanol, 5-chloro-2-(2-fluorophenyl)-7,8-dihydro- (9CI) (CA INDEX NAME)



IT **136742-06-8P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and saponification of)
RN 136742-06-8 CAPLUS
CN Furo[2,3-g]benzoxazole-7-carboxylic acid, 5-chloro-7,8-dihydro-2-phenyl-, ethyl ester (9CI) (CA INDEX NAME)

L17 ANSWER 23 OF 35 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



IT **114990-76-0P 136741-99-6P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation, chlorination and Jones oxidation of)
RN 114990-76-0 CAPLUS
CN Furo[2,3-g]benzoxazole-7-methanol, 4-chloro-7,8-dihydro-2-phenyl- (9CI) (CA INDEX NAME)



RN 136741-99-6 CAPLUS
CN Furo[2,3-g]benzoxazole-7-methanol, 4-chloro-2-(2-fluorophenyl)-7,8-dihydro- (9CI) (CA INDEX NAME)



IT **114990-72-6P 114990-77-1P 114990-79-3P 115005-75-9P 136741-36-1P 136741-37-2P 136741-38-3P 136741-39-4P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation, diuretic and uricosuric activity of)
RN 114990-72-6 CAPLUS
CN Furo[2,3-g]benzoxazole-7-carboxylic acid, 4-chloro-2-(4-fluorophenyl)-7,8-dihydro- (9CI) (CA INDEX NAME)

L17 ANSWER 23 OF 35 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 114990-77-1 CAPLUS
CN Furo[2,3-g]benzoxazole-7-carboxylic acid, 4-chloro-7,8-dihydro-2-phenyl- (9CI) (CA INDEX NAME)



RN 114990-79-3 CAPLUS
CN Furo[2,3-g]benzoxazole-7-carboxylic acid, 4,5-dichloro-7,8-dihydro-2-phenyl- (9CI) (CA INDEX NAME)



RN 115005-75-9 CAPLUS
CN Furo[2,3-g]benzoxazole-7-carboxylic acid, 7,8-dihydro-2-(2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 136741-36-1 CAPLUS

L17 ANSWER 23 OF 35 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
CN Furo[2,3-g]benzoxazole-7-carboxylic acid, 5-chloro-7,8-dihydro-2-phenyl- (9CI) (CA INDEX NAME)



RN 136741-37-2 CAPLUS
CN Furo[2,3-g]benzoxazole-7-carboxylic acid, 4,5-dichloro-2-(2-fluorophenyl)-7,8-dihydro- (9CI) (CA INDEX NAME)



RN 136741-38-3 CAPLUS
CN Furo[2,3-g]benzoxazole-7-carboxylic acid, 2-(2-fluorophenyl)-7,8-dihydro- (9CI) (CA INDEX NAME)



RN 136741-39-4 CAPLUS
CN Furo[2,3-g]benzoxazole-7-carboxylic acid, 5-chloro-2-(2-fluorophenyl)-7,8-dihydro- (9CI) (CA INDEX NAME)

L17 ANSWER 23 OF 35 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



IT **136742-01-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation, reaction with trichloroisocyanuric acid and Jones oxidation of)
RN 136742-01-3 CAPLUS
CN Furo[2,3-g]benzoxazole-7-methanol, 2-(2-fluorophenyl)-7,8-dihydro- (9CI) (CA INDEX NAME)



L17 ANSWER 24 OF 35 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1991:526400 CAPLUS
DOCUMENT NUMBER: 115:126400
TITLE: Studies on uricosuric diuretics. 4. Three-dimensional structure-activity relationships and receptor mapping of (aryloxy)acetic acid diuretics
AUTHOR(S): Koga, Hiroshi; Sato, Haruhiko; Dan, Takashi; Aoki, Bunya
CORPORATE SOURCE: Fuji-gotemba Res. Lab., Chugai Pharm. Co., Ltd., Shizuoka, 412, Japan
SOURCE: Journal of Medicinal Chemistry (1991), 34(9), 2702-8
CODEN: JMCMAR; ISSN: 0022-2623
DOCUMENT TYPE: Journal
LANGUAGE: English
GI


I


II


III

AB A receptor model was created for (aryloxy)acetic acid diuretics based on the enhanced diuretic activity of indacrinone (I) and a tienilic acid analog (II) when compared with tienilic acid (III). The degree of fitting to this receptor model was related to the diuretic activity of a series of (aryloxy)acetic acid analogs. Studies with addnl. analogs led to a modification of the receptor model which should be useful for future drug design.
IT **114990-79-3**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
(Uses)
(diuretic activity of, structure in relation to, receptor model for

L17 ANSWER 24 OF 35 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
prediction of)
RN 114990-79-3 CAPLUS
CN Furo[2,3-g]benzoxazole-7-carboxylic acid, 4,5-dichloro-7,8-dihydro-2-phenyl- (9CI) (CA INDEX NAME)



L17 ANSWER 25 OF 35 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1990:542429 CAPLUS
DOCUMENT NUMBER: 113:142429
TITLE: Cyanine compounds for optical recording media
INVENTOR(S): Manabe, Osamu; Fujita, Shigeo; Iwata, Shizuo; Kamiyama, Morihiro
PATENT ASSIGNEE(S): Asahi Chemical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 26 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9002777	A1	19900322	WO 1989-JP918	19890906
W: US				
RW: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
JP 02229865	A2	19900912	JP 1989-230704	19890905
JP 2843855	B2	19990106		
EP 387360	A1	19900919	EP 1989-910205	19890906
EP 387360	B1	19940112		
R: DE, FR, GB, NL				
US 5087704	A	19920211	US 1990-474094	19900504
PRIORITY APPLN. INFO.:			JP 1988-227091	19880909
			WO 1989-JP918	19890906

GI


I

AB The title compds. have the general formula I [R1 = H, lower alkyl; R2 = (un)substituted lower alkyl; X, Y = CH2, O; Z = acidic residue; n = 2, 3].
IT **129013-94-1P 129583-83-1P**
RL: PREP (Preparation)
(manufacture of, for optical recording media)
RN 129013-94-1 CAPLUS
CN 2H-Furo[2,3-f]indolium, 5-butyl-6-[5-(5-butyl-2,3,5,7-tetrahydro-2,7,7-trimethyl-6H-furo[2,3-f]indol-6-ylidene)-1,3-pentadienyl]-3,7-dihydro-2,7,7-trimethyl-, perchlorate (9CI) (CA INDEX NAME)

CM 1

CRN 129013-93-0
CMF C39 H51 N2 O2

L17 ANSWER 25 OF 35 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



CM 2

CRN 14797-73-0
CMF Cl O4

RN 129583-83-1 CAPLUS
CN 2H-Furo[2,3-f]indolium, 5-butyl-6-[7-(5-butyl-2,3,5,7-tetrahydro-7,7-dimethyl-6H-furo[2,3-f]indol-6-ylidene)-1,3,5-heptatrienyl]-3,7-dihydro-7,7-dimethyl-, ethyl sulfate (9CI) (CA INDEX NAME)

CM 1

CRN 129583-82-0
CMF C39 H49 N2 O2



CM 2

CRN 48028-76-8
CMF C2 H5 O4 S



IT **129583-68-2 129583-81-9**
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with anilinoacroleinanil)

L17 ANSWER 25 OF 35 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
RN 129583-68-2 CAPLUS
CN 2H-Furo[2,3-f]indolium, 5-butyl-3,7-dihydro-2,6,7,7-tetramethyl-, perchlorate (9CI) (CA INDEX NAME)

CM 1

CRN 129583-67-1
CMF C18 H26 N O



CM 2

CRN 14797-73-0
CMF Cl O4

RN 129583-81-9 CAPLUS
CN 2H-Furo[2,3-f]indolium, 5-butyl-3,7-dihydro-2,6,7,7-tetramethyl-, ethyl sulfate (9CI) (CA INDEX NAME)

CM 1

CRN 129583-67-1
CMF C18 H26 N O



L17 ANSWER 25 OF 35 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
CM 2

CRN 48028-76-8
CMF C2 H5 O4 S

L17 ANSWER 26 OF 35 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1990:515080 CAPLUS
DOCUMENT NUMBER: 113:115080
TITLE: Preparation of indolenine derivatives as dye intermediates
INVENTOR(S): Manabe, Osamu; Fujita, Shigeo; Iwata, Shizuo; Kamiyama, Morihiro
PATENT ASSIGNEE(S): Asahi Chemical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 23 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9002735	A1	19900322	WO 1989-JP944	19890914
W: US				
RW: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
JP 02191252	A2	19900727	JP 1989-237742	19890913
JP 2849757	B2	19990127		
EP 387357	A1	19900919	EP 1989-910180	19890914
EP 387357	B1	19950405		
R: DE, FR, GB, NL				
US 5055589	A	19911008	US 1990-490591	19900514
PRIORITY APPLN. INFO.:			JP 1988-233275	19880916
			WO 1989-JP944	19890914

OTHER SOURCE(S): MARPAT 113:115080
GI



I

AB The title compds. I (R1 = H, alkyl; X = Y = methylene, O) are prepared as intermediates for near IR absorbing cyanine dyes useful in optical disk recording medium using a semiconductor laser. A mixture of 3,4-methylenedioxyaniline and 3-bromo-3-methyl-2-butanone in pyridine was heated at 50-55° for 5 h and then was refluxed for 10 h to give indolenine I (R1 = H, X = Y = O).
IT **129013-94-1P 129014-08-0P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 129013-94-1 CAPLUS
CN 2H-Furo[2,3-f]indolium, 5-butyl-6-[5-(5-butyl-2,3,5,7-tetrahydro-2,7,7-trimethyl-6H-furo[2,3-f]indol-6-ylidene)-1,3-pentadienyl]-3,7-dihydro-2,7,7-trimethyl-, perchlorate (9CI) (CA INDEX NAME)

CM 1

CRN 129013-93-0
CMF C39 H51 N2 O2

L17 ANSWER 26 OF 35 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



CM 2

CRN 14797-73-0
CMF Cl O4

RN 129014-08-0 CAPLUS
CN 2H-Furo[2,3-f]indolium, 5-butyl-6-[7-(5-butyl-2,3,5,7-tetrahydro-2,7,7-trimethyl-6H-furo[2,3-f]indol-6-ylidene)-1,3,5-heptatrienyl]-3,7-dihydro-2,7,7-trimethyl-, ethyl sulfate (9CI) (CA INDEX NAME)

CM 1

CRN 129014-07-9
CMF C41 H53 N2 O2

PAGE 1-A



PAGE 1-B



L17 ANSWER 26 OF 35 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
CM 2

CRN 48028-76-8
CMF C2 H5 O4 S

IT **129014-13-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as intermediate for cyanine dye)
RN 129014-13-7 CAPLUS
CN 2H-Furo[2,3-f]indole, 3,7-dihydro-2,6,7,7-tetramethyl- (9CI) (CA INDEX NAME)



L17 ANSWER 27 OF 35 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1988:422956 CAPLUS
DOCUMENT NUMBER: 109:22956
TITLE: Preparation of 2-phenylfuro[2,3-g]benzoxazole derivativea having diuretic, antihypertensive, and uric acid-secreting activity
INVENTOR(S): Sato, Haruhiko; Koga, Hiroshi; Dan, Takashi; Konuma, Etsuro
PATENT ASSIGNEE(S): Chugai Pharmaceutical Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 6 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 62246581	A2	19871027	JP 1986-89082	19860417
PRIORITY APPLN. INFO.:			JP 1986-89082	19860417

GI



AB The title compds. [I; R1 = (halo or alkyl)Ph; R2, R3 = H, halo; R4 = HOCH2, HO2C, lower alkoxycarbonyl], having antihypertensive, diuretic, and uric acid-secreting activity (no data), were prepared A mixture of 4-chloro-2-(2-fluorophenyl)-6-hydroxybenzoxazole, K2CO3, and CH2:CHCH2Br in DMF was stirred 2.5 h at 50-60° to give 6-allyloxy-4-chloro-2-(2-fluorophenyl)benzoxazole (II). II in PhNMe2 was refluxed 6 h to give 7-allyl-4-chloro-2-(2-fluorophenyl)-6-hydroxybenzoxazole which was epoxidized with m-ClC6H4C(O)OOH in CH2Cl2 and then cyclized under reflux to give I (R1 = 2-FC6H4, R2 = Cl, R3 = H, R4 = HOCH2).
IT **114990-88-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and saponification of)
RN 114990-88-4 CAPLUS
CN Furo[2,3-g]benzoxazole-7-methanol, 4,5-dichloro-7,8-dihydro-2-phenyl-, acetate (ester) (9CI) (CA INDEX NAME)

L17 ANSWER 27 OF 35 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



IT **114990-71-5P 114990-72-6P 114990-73-7P**
114990-74-8P 114990-75-9P 114990-76-0P
114990-77-1P 114990-78-2P 114990-79-3P
114990-80-6P 114990-81-7P 114990-82-8P
114990-83-9P 115005-74-8P 115005-75-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as antihypertensive, diuretic, and for treatment of uricemia)
RN 114990-71-5 CAPLUS
CN Furo[2,3-g]benzoxazole-7-methanol, 4-chloro-2-(4-fluorophenyl)-7,8-dihydro- (9CI) (CA INDEX NAME)



RN 114990-72-6 CAPLUS
CN Furo[2,3-g]benzoxazole-7-carboxylic acid, 4-chloro-2-(4-fluorophenyl)-7,8-dihydro- (9CI) (CA INDEX NAME)



RN 114990-73-7 CAPLUS
CN Furo[2,3-g]benzoxazole-7-methanol, 4,5-dichloro-2-(4-fluorophenyl)-7,8-dihydro- (9CI) (CA INDEX NAME)

L17 ANSWER 27 OF 35 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 114990-74-8 CAPLUS
CN Furo[2,3-g]benzoxazole-7-carboxylic acid, 4,5-dichloro-2-(4-fluorophenyl)-7,8-dihydro- (9CI) (CA INDEX NAME)



RN 114990-75-9 CAPLUS
CN Furo[2,3-g]benzoxazole-7-carboxylic acid, 4,5-dichloro-2-(4-fluorophenyl)-7,8-dihydro-, ethyl ester (9CI) (CA INDEX NAME)



RN 114990-76-0 CAPLUS
CN Furo[2,3-g]benzoxazole-7-methanol, 4-chloro-7,8-dihydro-2-phenyl- (9CI) (CA INDEX NAME)



RN 114990-77-1 CAPLUS
CN Furo[2,3-g]benzoxazole-7-carboxylic acid, 4-chloro-7,8-dihydro-2-phenyl-

L17 ANSWER 27 OF 35 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
(9CI) (CA INDEX NAME)



RN 114990-78-2 CAPLUS
CN Furo[2,3-g]benzoxazole-7-methanol, 4,5-dichloro-7,8-dihydro-2-phenyl- (9CI) (CA INDEX NAME)



RN 114990-79-3 CAPLUS
CN Furo[2,3-g]benzoxazole-7-carboxylic acid, 4,5-dichloro-7,8-dihydro-2-phenyl- (9CI) (CA INDEX NAME)



RN 114990-80-6 CAPLUS
CN Furo[2,3-g]benzoxazole-7-methanol, 2-(4-fluorophenyl)-7,8-dihydro- (9CI) (CA INDEX NAME)

L17 ANSWER 27 OF 35 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
(9CI) (CA INDEX NAME)



RN 115005-75-9 CAPLUS
CN Furo[2,3-g]benzoxazole-7-carboxylic acid, 7,8-dihydro-2-(2-methylphenyl)- (9CI) (CA INDEX NAME)



L17 ANSWER 27 OF 35 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 114990-81-7 CAPLUS
CN Furo[2,3-g]benzoxazole-7-carboxylic acid, 2-(4-fluorophenyl)-7,8-dihydro- (9CI) (CA INDEX NAME)



RN 114990-82-8 CAPLUS
CN Furo[2,3-g]benzoxazole-7-carboxylic acid, 5-chloro-2-(4-fluorophenyl)-7,8-dihydro- (9CI) (CA INDEX NAME)



RN 114990-83-9 CAPLUS
CN Furo[2,3-g]benzoxazole-7-methanol, 7,8-dihydro-2-(2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 115005-74-8 CAPLUS
CN Furo[2,3-g]benzoxazole-7-methanol, 5-chloro-2-(4-fluorophenyl)-7,8-dihydro-

L17 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1988:112227 CAPLUS
DOCUMENT NUMBER: 108:112227
TITLE: Preparation and formulation of oxindolecarboxamides and derivatives as antiinflammatory agents
INVENTOR(S): Melvin, Lawrence S., Jr.
PATENT ASSIGNEE(S): Pfizer Inc., USA
SOURCE: U.S., 21 pp. Cont.-in-part of U.S. 4,644,005.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4686224	A	19870811	US 1985-762998	19850806
US 4644005	A	19870217	US 1984-666953	19841031
IL 76854	A1	19890515	IL 1985-76854	19851028
IL 87997	A1	19900726	IL 1985-87997	19851028
EP 181136	A2	19860514	EP 1985-307794	19851029
EP 181136	A3	19871028		
EP 181136	B1	19920325		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
PL 145239	B1	19880831	PL 1985-255990	19851029
PL 150842	B1	19900731	PL 1985-262327	19851029
AT 74128	E	19920415	AT 1985-307794	19851029
DK 8504976	A	19860501	DK 1985-4976	19851030
DK 163990	B	19920427		
DK 163990	C	19920921		
FI 8504258	A	19860501	FI 1985-4258	19851030
FI 81340	B	19900629		
FI 81340	C	19901010		
AU 8549189	A1	19860508	AU 1985-49189	19851030
AU 555051	B2	19860911		
JP 61109767	A2	19860528	JP 1985-243813	19851030
JP 03078854	B4	19911217		
HU 39428	A2	19860929	HU 1985-4158	19851030
HU 194168	B	19880128		
CA 1247099	A1	19881220	CA 1985-494220	19851030
ES 554609	A1	19870816	ES 1986-554609	19860430

PRIORITY APPLN. INFO.: US 1984-666953 19841031
US 1985-762998 19850806
IL 1985-76854 19851028
EP 1985-307794 19851029

OTHER SOURCE(S): CASREACT 108:112227
GI

L17 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



I II III

AB Title compds. I [R1 = C1-3 alkyl, Ph; R2 = (un)substituted Ph, pyridyl, 2-thiazolyl, 5-methyl-2-thiazolyl; Z = O, CH2], II (R3 = R2), and III [R3 = (un)substituted Ph, 2-thiazolyl, 5-methyl-2-thiazolyl, -3-isoxazolyl, 2-thiadiazolyl, 2-pyrimidyl; R4 = C2-6 alkanoyl, C4-6 cycloalkanoyl, C2-3 alkoxycarbonyl, 2-thenoyl, (un)substituted benzoyl, thenylacetyl, at 5-, 6-, 7-position of oxindole; R5 = H, C1-3 alkyl] and their salts, useful as antiinflammatory agents (no data), were prepared Et 5-benzoyloxindole-3-carboxylate and 4-FC6H4NH2 in C6H6 were heated to reflux, the reaction cooled, HCl added, and the organic phase separated to give III (R3 = 4-FC6H4; R4 = 5-benzoyl; R5 = Et).

IT **104019-05-8P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and addition reaction of, with difluorophenyl isocyanate)

RN 104019-05-8 CAPLUS

CN 2H-Furo[2,3-f]indole-3,6-dione, 5-ethyl-5,7-dihydro- (9CI) (CA INDEX NAME)



IT **104018-22-6P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as inflammation inhibitor)

RN 104018-22-6 CAPLUS

CN 2H-Furo[2,3-f]indole-7-carboxamide, 5-ethyl-N-(4-fluorophenyl)-3,5,6,7-tetrahydro-3,6-dioxo- (9CI) (CA INDEX NAME)



L17 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

L17 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1986:552922 CAPLUS
DOCUMENT NUMBER: 105:152922
TITLE: Oxindole antiinflammatory agents
INVENTOR(S): Lawrence, Melvin Sherman, Jr.
PATENT ASSIGNEE(S): Pfizer Inc., USA
SOURCE: Eur. Pat. Appl., 68 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 181136	A2	19860514	EP 1985-307794	19851029
EP 181136	A3	19871028		
EP 181136	B1	19920325		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
US 4644005	A	19870217	US 1984-666953	19841031
US 4686224	A	19870811	US 1985-762998	19850806
AT 74128	E	19920415	AT 1985-307794	19851029
PRIORITY APPLN. INFO.:			US 1984-666953	19841031
			US 1985-762998	19850806
			EP 1985-307794	19851029

OTHER SOURCE(S): CASREACT 105:152922

GI



AB Oxindolecarboxamide derivs. RCONHR1 [I; R = Q-Q2; R1 = pyridyl, 2-thiazolyl, 5-methyl-2-thiazolyl, 2-thiadiazolyl, 2-pyrimidyl, (un)substituted Ph; R2 = Ph, alkyl; R3 = alkanoyl, cycloalkanoyl, alkoxycarbonyl, 2-thenoyl, PhCH2CO, (un)substituted Bz; R4 = H, alkyl; Z = O, CH2] are prepared as antiinflammatory agents (no data). Thus, cyclopenta[f]indole derivative II (prepared in 5 steps from 1-ethyloxindole) was added to NaH in DMF, followed by 2,4-F2C6H3NCO, to give 79% I (R = Q, R1 = 2,4-F2C6H3, R2 = Et, Z = CH2). Approx. 74 other I and several synthetic intermediates are also prepared

IT **104019-05-8P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

L17 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 104019-05-8 CAPLUS

CN 2H-Furo[2,3-f]indole-3,6-dione, 5-ethyl-5,7-dihydro- (9CI) (CA INDEX NAME)



IT **104018-22-6P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as antiinflammatory agent)

RN 104018-22-6 CAPLUS

CN 2H-Furo[2,3-f]indole-7-carboxamide, 5-ethyl-N-(4-fluorophenyl)-3,5,6,7-tetrahydro-3,6-dioxo- (9CI) (CA INDEX NAME)



L17 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1986:442772 CAPLUS
DOCUMENT NUMBER: 105:42772
TITLE: Furoindolone antiinflammatory agents
INVENTOR(S): Lawrence, Melvin S., Jr.
PATENT ASSIGNEE(S): Pfizer Inc., USA
SOURCE: Eur. Pat. Appl., 52 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 173520	A2	19860305	EP 1985-305830	19850816
EP 173520	A3	19860514		
EP 173520	B1	19900103		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
WO 8601510	A1	19860313	WO 1984-US1371	19840824
W: FI, HU, US				
HU 47580	A2	19890328	HU 1984-4219	19840824
HU 203238	B	19910628		
AT 49211	E	19900115	AT 1985-305830	19850816
CA 1244427	A1	19881108	CA 1985-489226	19850822
PL 147393	B1	19890531	PL 1985-255089	19850822
PL 147395	B1	19890531	PL 1985-260270	19850822
DK 8503826	A	19860225	DK 1985-3826	19850823
DK 160098	B	19910128		
DK 160098	C	19910624		
JP 61057554	A2	19860324	JP 1985-185619	19850823
JP 04050316	B4	19920813		
ES 546377	A1	19870401	ES 1985-546377	19850823
ZA 8506403	A	19870429	ZA 1985-6403	19850823
IL 76175	A1	19890815	IL 1985-76175	19850823
IL 87402	A1	19890815	IL 1985-87402	19850823
IL 87403	A1	19890815	IL 1985-87403	19850823
IL 87404	A1	19890815	IL 1985-87404	19850823
AU 8546637	A1	19860227	AU 1985-46637	19850826
AU 553859	B2	19860731		
ES 552044	A1	19870601	ES 1986-552044	19860214
US 4695571	A	19870922	US 1986-867185	19860402
FI 8601704	A	19860423	FI 1986-1704	19860423
FI 79319	B	19890831		
FI 79319	C	19891211		

PRIORITY APPLN. INFO.: WO 1984-US1371 19840824
EP 1985-305830 19850816
IL 1985-76175 19850823

OTHER SOURCE(S): CASREACT 105:42772
GI



AB Fused oxindoles I (Z = N, CH, CMe; Z1 = O, S; R = alkyl, Ph; R1 = Ph, halo- or methoxyphenyl, heteroaryl, etc.; R2 = H, Me), useful as antiinflammatory agent (no data), were prepared Furoindolone II (R3 = H) was treated with 4-ClC6H4NCO at 25° to give II (R3 = CONHC6H4Cl-4).

IT **103113-85-5P 103113-94-6P 103113-95-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, as inflammation inhibitor)

RN 103113-85-5 CAPLUS
CN 2H-Furo[2,3-f]indole-7-carboxamide, 5-ethyl-3,5,6,7-tetrahydro-N-[4-(methylthio)phenyl]-6-oxo- (9CI) (CA INDEX NAME)



RN 103113-94-6 CAPLUS
CN 2H-Furo[2,3-f]indole-7-carboxamide, 5-ethyl-3,5,6,7-tetrahydro-N-[3-(methylthio)phenyl]-6-oxo- (9CI) (CA INDEX NAME)



RN 103113-95-7 CAPLUS
CN 2H-Furo[2,3-f]indole-7-carboxamide, 5-ethyl-3,5,6,7-tetrahydro-N-[2-(methylthio)phenyl]-6-oxo- (9CI) (CA INDEX NAME)

L17 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



IT **103113-42-4P 103113-44-6P 103113-71-9P**
103113-72-0P 103113-73-1P 103113-74-2P
103113-75-3P 103113-76-4P 103113-77-5P
103113-78-6P 103113-79-7P 103113-80-0P
103113-81-1P 103113-82-2P 103113-83-3P
103113-84-4P 103113-86-6P 103113-87-7P
103113-88-8P 103113-89-9P 103113-90-2P
103113-91-3P 103113-92-4P 103113-93-5P
103113-96-8P 103113-97-9P 103113-98-0P
103113-99-1P 103114-01-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as inflammation inhibitor)

RN 103113-42-4 CAPLUS
CN 2H-Furo[2,3-f]indole-7-carboxamide, N-(4-chlorophenyl)-5-ethyl-3,5,6,7-tetrahydro-6-oxo- (9CI) (CA INDEX NAME)



RN 103113-44-6 CAPLUS
CN 2H-Furo[2,3-f]indole-7-carboxamide, 5-ethyl-N-(4-fluorophenyl)-3,5,6,7-tetrahydro-2-methyl-6-oxo- (9CI) (CA INDEX NAME)



RN 103113-71-9 CAPLUS
CN 2H-Furo[2,3-f]indole-7-carboxamide, 5-ethyl-3,5,6,7-tetrahydro-2,2-dimethyl-N-(5-methyl-2-thiazolyl)-6-oxo- (9CI) (CA INDEX NAME)

L17 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 103113-72-0 CAPLUS
CN 2H-Furo[2,3-f]indole-7-carboxamide, 5-ethyl-3,5,6,7-tetrahydro-N-(5-methyl-2-thiazolyl)-6-oxo- (9CI) (CA INDEX NAME)



RN 103113-73-1 CAPLUS
CN 2H-Furo[2,3-f]indole-7-carboxamide, 5-ethyl-N-(4-fluorophenyl)-3,5,6,7-tetrahydro-6-oxo- (9CI) (CA INDEX NAME)



RN 103113-74-2 CAPLUS
CN 2H-Furo[2,3-f]indole-7-carboxamide, N-(2,4-difluorophenyl)-5-ethyl-3,5,6,7-tetrahydro-6-oxo- (9CI) (CA INDEX NAME)



RN 103113-75-3 CAPLUS

L17 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
CN 2H-Furo[2,3-f]indole-7-carboxamide, 5-ethyl-N-(2-fluorophenyl)-3,5,6,7-tetrahydro-6-oxo- (9CI) (CA INDEX NAME)



RN 103113-76-4 CAPLUS
CN 2H-Furo[2,3-f]indole-7-carboxamide, 5-ethyl-N-(3-fluorophenyl)-3,5,6,7-tetrahydro-6-oxo- (9CI) (CA INDEX NAME)



RN 103113-77-5 CAPLUS
CN 2H-Furo[2,3-f]indole-7-carboxamide, N-(2,6-difluorophenyl)-5-ethyl-3,5,6,7-tetrahydro-6-oxo- (9CI) (CA INDEX NAME)



RN 103113-78-6 CAPLUS
CN 2H-Furo[2,3-f]indole-7-carboxamide, 5-ethyl-3,5,6,7-tetrahydro-N-(4-methoxyphenyl)-6-oxo- (9CI) (CA INDEX NAME)

L17 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 103113-79-7 CAPLUS
CN 2H-Furo[2,3-f]indole-7-carboxamide, 5-ethyl-3,5,6,7-tetrahydro-6-oxo-N-phenyl- (9CI) (CA INDEX NAME)



RN 103113-80-0 CAPLUS
CN 2H-Furo[2,3-f]indole-7-carboxamide, 5-ethyl-3,5,6,7-tetrahydro-N-(3-methoxyphenyl)-6-oxo- (9CI) (CA INDEX NAME)



RN 103113-81-1 CAPLUS
CN 2H-Furo[2,3-f]indole-7-carboxamide, N-(2,5-difluorophenyl)-5-ethyl-3,5,6,7-tetrahydro-6-oxo- (9CI) (CA INDEX NAME)

L17 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 103113-82-2 CAPLUS
CN 2H-Furo[2,3-f]indole-7-carboxamide, 5-ethyl-3,5,6,7-tetrahydro-N-(2-methoxyphenyl)-6-oxo- (9CI) (CA INDEX NAME)



RN 103113-83-3 CAPLUS
CN 2H-Furo[2,3-f]indole-7-carboxamide, 5-ethyl-3,5,6,7-tetrahydro-6-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 103113-84-4 CAPLUS
CN 2H-Furo[2,3-f]indole-7-carboxamide, N-(3-acetylphenyl)-5-ethyl-3,5,6,7-tetrahydro-6-oxo- (9CI) (CA INDEX NAME)



L17 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
RN 103113-86-6 CAPLUS
CN 2H-Furo[2,3-f]indole-7-carboxamide, N-(4-acetylphenyl)-5-ethyl-3,5,6,7-tetrahydro-6-oxo- (9CI) (CA INDEX NAME)



RN 103113-87-7 CAPLUS
CN 2H-Furo[2,3-f]indole-7-carboxamide, 5-ethyl-3,5,6,7-tetrahydro-6-oxo-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 103113-88-8 CAPLUS
CN 2H-Furo[2,3-f]indole-7-carboxamide, N-(2-acetylphenyl)-5-ethyl-3,5,6,7-tetrahydro-6-oxo- (9CI) (CA INDEX NAME)



RN 103113-89-9 CAPLUS
CN 2H-Furo[2,3-f]indole-7-carboxamide, 5-ethyl-3,5,6,7-tetrahydro-6-oxo-N-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

L17 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 103113-90-2 CAPLUS
CN Benzoic acid,
3-[[(5-ethyl-3,5,6,7-tetrahydro-6-oxo-2H-furo[2,3-f]indol-7-yl)carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 103113-91-3 CAPLUS
CN Benzoic acid,
4-[[(5-ethyl-3,5,6,7-tetrahydro-6-oxo-2H-furo[2,3-f]indol-7-yl)carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 103113-92-4 CAPLUS
CN Benzoic acid,
2-[[(5-ethyl-3,5,6,7-tetrahydro-6-oxo-2H-furo[2,3-f]indol-7-yl)carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)

L17 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 103113-93-5 CAPLUS
CN 2H-Furo[2,3-f]indole-7-carboxamide, 5-ethyl-N-(3-fluoro-4-methoxyphenyl)-3,5,6,7-tetrahydro-6-oxo- (9CI) (CA INDEX NAME)



RN 103113-96-8 CAPLUS
CN 2H-Furo[2,3-f]indole-7-carboxamide, 5-ethyl-3,5,6,7-tetrahydro-6-oxo-N-2-pyridinyl- (9CI) (CA INDEX NAME)



RN 103113-97-9 CAPLUS
CN 2H-Furo[2,3-f]indole-7-carboxamide, 5-ethyl-3,5,6,7-tetrahydro-N-[4-(methylsulfinyl)phenyl]-6-oxo- (9CI) (CA INDEX NAME)

L17 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 103113-98-0 CAPLUS
CN 2H-Furo[2,3-f]indole-7-carboxamide, 5-ethyl-3,5,6,7-tetrahydro-N-[3-(methylsulfinyl)phenyl]-6-oxo- (9CI) (CA INDEX NAME)



RN 103113-99-1 CAPLUS
CN 2H-Furo[2,3-f]indole-7-carboxamide, 5-ethyl-3,5,6,7-tetrahydro-N-[2-(methylsulfinyl)phenyl]-6-oxo- (9CI) (CA INDEX NAME)



RN 103114-01-8 CAPLUS
CN 2H-Furo[2,3-f]indole-7-carboxamide, 5-ethyl-N-(4-fluorophenyl)-3,5,6,7-tetrahydro-2,2-dimethyl-6-oxo- (9CI) (CA INDEX NAME)



IT **103113-43-5 103113-45-7 103114-00-7**

L17 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of)

RN 103113-43-5 CAPLUS
CN 6H-Furo[2,3-f]indol-6-one, 5-ethyl-2,3,5,7-tetrahydro- (9CI) (CA INDEX NAME)



RN 103113-45-7 CAPLUS
CN 6H-Furo[2,3-f]indol-6-one, 5-ethyl-2,3,5,7-tetrahydro-2-methyl- (9CI) (CA INDEX NAME)



RN 103114-00-7 CAPLUS
CN 6H-Furo[2,3-f]indol-6-one, 5-ethyl-2,3,5,7-tetrahydro-2,2-dimethyl- (9CI) (CA INDEX NAME)



L17 ANSWER 31 OF 35 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1984:6360 CAPLUS
DOCUMENT NUMBER: 100:6360
TITLE: Preparation of new dihydrofuro[2,3-f]indole derivatives
AUTHOR(S): Plattner, J. J.; Parks, J. A.
CORPORATE SOURCE: Dep. Med. Chem., Abbott Lab., North Chicago, IL, 60064, USA
SOURCE: Journal of Heterocyclic Chemistry (1983), 20(4), 1059-62
CODEN: JHTCAD; ISSN: 0022-152X
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 100:6360
GI



I

AB The preparation of new dihydrofuro[2,3-f]indole derivs. e.g., I and their fully aromatic counterparts is described. Key steps in the synthesis include a Claisen rearrangement/m-chloroperoxybenzoic acid oxidation sequence to form a dihydrobenzofuran intermediate and an Fe/HOAc reductive cyclization to generate the dihydrofuro[2,3-f]indole nucleus. Introduction of a 5-Ph substituent on the indole nitrogen was effected by a modified Ullmann reaction. Fully aromatic furo[2,3-f]indoles were obtained from the dihydro congeners by dehydrogenation with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone.

IT **88062-25-3P 88062-26-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and dehydrogenation of)

RN 88062-25-3 CAPLUS
CN 2H-Furo[2,3-f]indole-2-carboxylic acid, 8-chloro-3,5-dihydro-, methyl ester (9CI) (CA INDEX NAME)

L17 ANSWER 31 OF 35 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 88062-26-4 CAPLUS
CN 2H-Furo[2,3-f]indole-2-carboxylic acid, 8-chloro-3,5-dihydro-5-phenyl-, methyl ester (9CI) (CA INDEX NAME)



IT **88062-21-9P 88062-22-0P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, with iodobenzene)

RN 88062-21-9 CAPLUS
CN 2H-Furo[2,3-f]indole-2-methanol, 8-chloro-3,5-dihydro-, acetate (ester) (9CI) (CA INDEX NAME)



RN 88062-22-0 CAPLUS
CN 2H-Furo[2,3-f]indole-2-methanol, 8-chloro-3,5-dihydro- (9CI) (CA INDEX NAME)

L17 ANSWER 31 OF 35 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



IT **88062-23-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 88062-23-1 CAPLUS
CN 2H-Furo[2,3-f]indole-2-methanol, 8-chloro-3,5-dihydro-5-phenyl- (9CI) (CA INDEX NAME)



L17 ANSWER 32 OF 35 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1983:422350 CAPLUS
DOCUMENT NUMBER: 99:22350
TITLE: Reaction of a cyclic hemiaminal with CH-acidic compounds
AUTHOR(S): Kucklaender, Uwe
CORPORATE SOURCE: Inst. Pharm. Chem., Univ. Duesseldorf, Duesseldorf, D-4000/1, Fed. Rep. Ger.
SOURCE: Archiv der Pharmazie (Weinheim, Germany) (1983), 316(5), 449-53
CODEN: ARPMAS; ISSN: 0365-6233
DOCUMENT TYPE: Journal
LANGUAGE: German
GI



I II III

AB The cyclic quinonecarbinolamine I underwent cyclization with F3CCOCH2COR (R = CF3, Me, OEt) gave the furoindole II. The hemiketal structure of II was proven by 13C NMR. I (R = F3C) on treatment with Ac2O gave the furoindole III. I (R = Me) reacted with Ac2O to give the acetate.

IT **86069-23-0P**
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(preparation and carbon-13 NMR of)

RN 86069-23-0 CAPLUS
CN 2H-Furo[3,2-e]indole-8-carboxylic acid, 1-acetyl-2-(acetyloxy)-1,6-dihydro-6,7-dimethyl-2-(trifluoromethyl)-, ethyl ester (9CI) (CA INDEX NAME)

L17 ANSWER 32 OF 35 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



IT **86069-21-8P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 86069-21-8 CAPLUS
CN 2H-Furo[3,2-e]indole-1,8-dicarboxylic acid, 1,6-dihydro-2-hydroxy-6,7-dimethyl-2-(trifluoromethyl)-, diethyl ester (9CI) (CA INDEX NAME)



IT **86069-22-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation, acetylation, and carbon-13 NMR of)
RN 86069-22-9 CAPLUS
CN 2H-Furo[3,2-e]indole-8-carboxylic acid, 1-acetyl-1,6-dihydro-2-hydroxy-6,7-dimethyl-2-(trifluoromethyl)-, ethyl ester (9CI) (CA INDEX NAME)



IT **86069-19-4P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation, dehydration, and carbon-13 NMR of)

L17 ANSWER 32 OF 35 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
RN 86069-19-4 CAPLUS
CN 2H-Furo[3,2-e]indole-8-carboxylic acid, 1,6-dihydro-2-hydroxy-6,7-dimethyl-1-(trifluoroacetyl)-2-(trifluoromethyl)-, ethyl ester (9CI) (CA INDEX NAME)



L17 ANSWER 33 OF 35 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1974:47100 CAPLUS
DOCUMENT NUMBER: 80:47100
TITLE: Electrophilic reactions in the indole series
AUTHOR(S): Julia, Marc; Lallemand, Jean Y.
CORPORATE SOURCE: Lab. Synth. Prod. Nat., Ec. Natl. Super. Chim. Paris, Paris, Fr.
SOURCE: Bulletin de la Societe Chimique de France (1973), (6)(Pt. 2), 2046-57
CODEN: BSCFAS; ISSN: 0037-8968
DOCUMENT TYPE: Journal
LANGUAGE: French
OTHER SOURCE(S): CASREACT 80:47100
AB The reaction of several indol-5-ols with a variety of reactive electrophiles resulted in the introduction of a functional chain in the 3-
or 4-position. Mechanisms were proposed for these reactions which include
the Mannich, Vilsmeier-Haack, Claisen, Friedel-Crafts, and Fries reactions, among others.
IT **51086-15-8P 51086-17-0P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 51086-15-8 CAPLUS
CN 2H-Furo[3,2-e]indole-7-carboxylic acid, 1,6-dihydro-1,2-dioxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 51086-17-0 CAPLUS
CN Spiro[1,3-dithiolane-2,1'(6'H)-[2H]furo[3,2-e]indole]-7'-carboxylic acid, 2'-oxo-, ethyl ester (9CI) (CA INDEX NAME)



L17 ANSWER 34 OF 35 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1973:478608 CAPLUS
DOCUMENT NUMBER: 79:78608
TITLE: Indoles
INVENTOR(S): Kimura, Michio; Inaba, Shigeho; Yamamoto, Hisao
PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd.
SOURCE: Jpn. Kokai Tokkyo Koho, 8 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 48040764	A2	19730615	JP 1971-78060	19711004
JP 50002987	B4	19750130		

PRIORITY APPLN. INFO.: JP 1971-78060 19711004
GI For diagram(s), see printed CA Issue.
AB The title compds. (I) (R1 = acyl, R2 = alkyl; R3, R4 = H or alkyl; X = CH2
or O; n = 1 or 2), antiinflammatory drugs, were prepared by dehydrating the
corresponding 1-acyl-3-hydroxyindoleacetic acids (II). E.g., II (R1 = cinnamoyl, R2 = Me, R3 = R4 = H, X = O, n = 1) in C6H6-Et2O was refluxed 7
hr with tert-Bu bromoacetate, Zn dust, and iodine to give the corresponding I. Similarly prepared were the following I (R1, R2, R3, R4,
X, and n given): p-ClC6H4CO, Me, H, H, O, 1; cinnamoyl, Me, H, Me, CH2, 1; Ac, Et, H, PhCH2, O, 1; 2-furanacryloyl, Me, Me, Et, O, 1; p-MeC6H4CO, Me, H, H, O, 2. Also prepared was 1-(p-chlorobenzoyl)-2-methyl-6,7-dihydrofuro[2,3-f]-3-indolylacetic acid.
IT **42598-05-0P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 42598-05-0 CAPLUS
CN 2H-Furo[2,3-f]indole-7-acetic acid, 5-(4-chlorobenzoyl)-6-ethyl-3,5-dihydro- (9CI) (CA INDEX NAME)



L17 ANSWER 35 OF 35 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1972:434323 CAPLUS
DOCUMENT NUMBER: 77:34323
TITLE: Antiinflammatory 3-(N-acylindolyl)acetic acid derivatives
INVENTOR(S): Kimura, Michio; Inaba, Shigeho; Yamamoto, Hisao
PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd.
SOURCE: Ger. Offen., 36 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2142196	A	19720302	DE 1971-2142196	19710823
DE 2142196	B2	19750626		
DE 2142196	C3	19760219		

PRIORITY APPLN. INFO.: DE 1971-2142196 19710823
GI For diagram(s), see printed CA Issue.
AB Twenty-six title compds. I (n = 0 or 1; X = CH2, O; Y = CH2, O; R = H, Me;
R1 = CH:CHPh, substituted phenyl, 1- or 5-indanyl, 2-pyridyl, alkenyl), were prepared by acylation of phenylhydrazones and condensation with the aliphatic keto carboxylic acid derivative, MeCOCH2CHRCO2H. I were effective
as antiinflammatory agents in rats and mice.
IT **37585-76-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 37585-76-5 CAPLUS
CN 2H-Furo[2,3-f]indole-7-acetic acid, 5-(4-chlorobenzoyl)-3,5-dihydro-6-methyl- (9CI) (CA INDEX NAME)